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A Committee of the American Thyroid Association (ATA) recently com-
pleted an up to date revision of Guidelines for the Management of Thy-
roid Nodules and Differentiated Thyroid Cancer [1]. The publication is
voluminous with some 100 different recommendations, each of which
is supported by summaries of the evidence available in the literature.
This lecture could describe a few highlights of the many important rec-
ommendations. In each case, suggested management was indicated by
both the strength of the recommendation (strong, weak, or none) and
the quality of the evidence (low, moderate, high, or insufficient). For ex-
ample, in a patient with a nodule about to undergo surgery, it is recom-
mended that a pre-operative ultrasound of the neck be performed to
delineate the contralateral lobe and the lymph nodes in the central
and lateral neck compartments, and this was a ‘strong’ recommenda-
tion based on ‘moderate’ quality evidence. A significant departure from
earlier guidelines is the recommendation that lobectomy rather than
total thyroidectomy can suffice for nodules that are indeterminate on
FNA (AUS/FLUS, follicular neoplasm) and also for nodules of <1 cm
even with biopsy proven cancer. However, total thyroidectomy is still
recommended for indeterminate nodules >4 cm, FNA positive thyroid
cancers >1 cm, nodules for which the FNA shows marked atypia, or
nodules in patients with a family history of thyroid cancer or a history
of radiation exposure to the neck. A summarized and practical ap-
proach to management of nodules appears in our recent report [2].
In addition to the use of AJCC/UICC staging of tumours, the Guidelines
recommend that risk of recurrence be predicted with the 3-tiered ATA
system of “low risk”, “intermediate risk”, and “high risk”. Another area of
departure from earlier guidelines is the recommendation that 131-Iodine
ablation is not necessary for most low risk tumours and even some less
aggressive intermediate risk tumours, but clearly is recommended for
high risk tumours. A decision for or against ablation may depend upon
the post-operative status as indicated by the suppressed or stimulated
serum level of thyroglobulin. The utility of post-operative, pre-ablation
scans is discussed, with 123-Iodine preferable to 131-Iodine in order to
avoid stunning. In regard to 131-Iodine therapy, lower doses are now
recommended on the basis of studies by Mallick et al. [3] and Schlum-
berger et al. [4] indicating that 30 mCi (1.11 GBq) is as effective for abla-
tion as are higher dose activities. Moreover, the recommendation is that
ablation should be done when feasible after facilitation by recombinant
human TSH, at least when given for low and intermediate risk patients.© The Author(s). 2016 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeFinally, the Guidelines focus on the importance of dynamic risk assess-
ment or essentially a re-staging during the long term follow-up of our pa-
tients. Patients are categorized by this method as either having had an
“excellent” response, a “biochemically incomplete” response, a “structur-
ally incomplete” response, or an “indeterminate” response. Based upon
this ongoing re-assessment, physicians will follow appropriately matched
measures for either further diagnostic procedures or for treatment.
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Thyroid disorders and breast cancer
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In 1896 Beatson used thyroid extract accompanied by oophorectomy
to treat breast cancer and thereby started a search for an association
between thyroid disorders and breast cancer which continues to this
day. However despite extensive studies frustratingly little evidence of
a causative link has emerged. Many reports have associated breast
cancer with hyperthyroidism, hypothyroidism, iodine deficiency and
nontoxic goitre with hypothyroidism being the predominant breast
related thyroid disorder [1,2]. This is not a universal finding as many
reports fail to detect an association between the two disorders [3].
One area where there is some, although far from universal agree-
ment, is the finding of an increased prevalence of antithyroid auto-
antibodies in breast cancer patients compared to controls [4]. This
report reviews published evidence for the coincidence of thyroid dis-
orders and breast cancer and highlights some areas which might
benefit from further exploration. Studies in Ireland over a 20 year
period (1990-2010) revealed a preponderance of both hypothyroidism
and nontoxic goitre in patients with breast cancer compared to age
matched controls [5]. Similarly TPO.Ab ± Tg.Ab were significantly
greater in patients with breast cancer (30.5%) or benign breast disease
(fibroadenoma 28.7%) compared to age matched controls (15.0% and
13.7% respectively) [6]. A previous report in an Irish breast cancer popu-
lation showed that the presence of TPO.Ab and increased ultrasound
measured thyroid volume was associated with improved outcome in
breast cancer and was supported by studies that women with high
levels of TPO.Ab had a lower risk of breast cancer with particularly bet-
ter outcome in advanced breast cancers [7,8]. TPO has been shown to
be expressed in breast cancer and it has been suggested that the ex-
pression of TPO in breast tissues may explain the protective role of
TPO.Ab in breast cancer [9]. In addition to the association of thyroid dis-
orders with breast cancer, it has been long suggested that a link be-
tween the two disorders is their common ability to concentrate iodide
[10,11]. The demonstration that breast tissue expressed the iodide
transporter NIS and that tissue iodine were found to be significantly
lower in malignant compared to benign breast tissue [12] supported
the suggestion that defects in iodine transport may have a role in
breast cancer pathogenesis [13,14].
In an attempt to elucidate if the presence of TPO.Ab in breast cancer
was an expression of a generalised immune response to the cancer
or a true indication of autoimmune thyroid disease the author ex-
plored the relevance as to the significance of detectable rather than
elevated levels of TPO.Ab in breast cancer [15,16]. Examining serum
TPO.Ab concentration and its relationship to TSH in patients with
postmenopausal breast cancer compared to postmenopausal con-
trols it emerged that there was an association, not only between ele-
vated TPO.Ab (>20.0 kIU/l) and serum TSH but that this association
also applied to those patients with breast cancer who had detectable
TPOAb (>2.0 < 20.0 kIU/l). Both TPO.Ab positivity and detectability
were increased in breast cancer patients, even when TSH was within
the upper 50% of the reference range (2.1-4.0 mU/l). The explanation
for increased TPO.Ab prevalence in breast cancer is unknown but on
the basis of serum TSH distribution, it may be associated with a sub-
tle thyroid dysfunction. These observations lead the author to con-
clude that the association between thyroid disorders and breast
cancer is based on more than chance. Coexisting autoimmune thy-
roid disease is the most likely candidate but it remains to be estab-
lished if this observation can offer a therapeutic opportunity.
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New thyroid hormone metabolites: biosynthesis, action, and
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Classical action of thyroid hormones (TH) on foetal and postnatal de-
velopment, especially of the brain, on growth, energy metabolism,
metabolic rate as well as on many anabolic and catabolic pathways
is thought to be exerted via T3–dependent modulation of the func-
tion of various nuclear, mitochondrial and cytosolic isoforms and iso-
types of T3 receptors (TR). These ligand-dependent transcription
factors eventually modulate expression of T3-regulated genes. L-
thyroxine (T4), the main product secreted by the human thyroid
gland, is considered as a “prohormone” devoid of inherent biological
activity with exception of its rapid activation of anb3 integrin recep-
tor signalling at the cell membrane. These integrin receptors also re-
spond to the T4 metabolite Tetrac, which is found in blood in
concentrations similar to those of T3. Reverse-T3, circulating in regu-
lated manner in the blood is also regarded as an inactive TH metab-
olite but may act in guidance and regulation of neuronal migration
during CNS development.
Recently, marked “thyromimetic” effects have been reported for 3,5-
T2, a “hot” metabolite putatively formed from T3. Via several mito-
chondrial targets 3,5-T2 rapidly stimulates mitochondrial function
and oxygen consumption, “cleans” steatotic livers from lipid accumu-
lation, improves hyperlipidemia and hypercholesterolemia in rodent
models and acts on skeletal muscle. 3,5-T2 has been reported to lack
thyromimetic action on cardiac function and the hypothalamus-
pituitary-thyroid (HPT) axis in various rat animal experimental models
[1]. The in vivo pathways of 3,5-T2 formation are still elusive, though
PTU inhibition of its formation and action indicates a contribution of
PTU-sensitive type 1 5’-deiodinase in its biosynthesis. However, these
alleged “beneficial” 3,5-T2 effects are still controversial as several
mouse and rat experimental studies indicate dose-dependent ad-
verse effects on the heart (increased weight, hypertrophy, altered
gene expression, fibrotic signs), intermediary metabolism and sup-
pression of the HPT axis. Therefore, the use of this compound, freely
available by internet or as OTC preparation in the body-building,
doping and wellness scene should be strongly discouraged and phy-
sicians need to be aware of potential abuse of 3,5-T2 by their patients
showing ‘abnormal’ thyroid function tests. A chemiluminescence im-
munoassay (CLIA) has recently been developed for 3,5-T2 [2] and its
first application in clinical studies revealed elevated 3,5-T2 serum con-
centrations under several conditions associated with the “low-T3 syn-
drome” or non-thyroidal illness.
3-iodothyronamine (3T1AM) is a decarboxylated “cool” TH metabolite
formed via combined deiodination and decarboxylation [3,4]. All
three deiodinases can handle thyronamines and ornithine decarb-
oxylase (ODC) as well as gastrointestinal mucosa have been pro-
posed to contribute to 3T1AM biosynthesis. 3T1AM, detected by CLIA
in human serum in low nanomolar concentrations has a long half-life
probably due to its binding to apolipoprotein B100. Serum 3T1AM
concentrations in patients on T4 replacement therapy are higher
than in healthy individuals and several correlations to metabolic pa-
rameters have been suggested. In animal models administration of
pharmacological doses of 3T1AM rapidly decrease body temperature,
increase glucagon and glucose but reduce insulin serum concentra-
tions and shift metabolism from carbohydrate to lipid oxidation. Sev-
eral behavioural effects on altered learning, pain sensation and
transmitter action have been described [5]. 3T1AM acts via several re-
ceptor systems such as trace amine-associated receptors (TAAR),
transient thermosensitive receptor potential melastatin 8 (TRPM8)
channel and α-2A-adrenergic receptor. Further CNS, metabolic and
cardiac effects have been reported for N-acetylated and acetic acid
metabolites of 3T1AM.Supported by grants of the Deutsche Forschungsgemeinschaft DFG
SPP 1629 ThyroidTransAct.
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Short-stay surgical goitre treatment. Possibilities and conditions
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Background
Operations have their recognised place in the treatment of goitre.
The indications for operative treatment have been the same for
many years. Advances in medicine and changes in surgical approach
have both influenced the development of minimally invasive tech-
niques. These have also affected the duration of hospital stay, short-
ening it significantly, and resulting in a reduction in the real financial
costs of the medical services provided.
Aims
The aim of study was to evaluate the use of short-stay (one-day)
surgery in patients with thyroid disorders requiring surgical treatment.
Material and methods
A prospective analysis was performed of two groups of operated patients
with a variety of thyroid conditions. One group consisted of patients
treated at the Short-stay Surgical Department of the St. John Grande Hos-
pital of Brothers Hospitallers, in Cracow. The second consisted of the ma-
terial of 500 patients operated on conventionally in the Department of
Table 2 (abstract A4). Clinical diagnosis of patients
Clinical Diagnosis HOSPITAL DEPT p
n % n %
Cancer (primary op.) 12 11.8 57 11.4 NS
Cancer (radicalisation) 1 1 4 0.8 NS
Nodular goitre 69 67.6 306 61.1 NS
Toxic nodular goitre 5 4.9 105 21.1 <0.001
Graves’ disease 0 0 9 1.8 NS
Inflammation of thyroid 13 12.7 1 0.2 <0.001
Recurrent goitre 2 2 18 3.6 NS
TOTAL 102 100 500 100
Table 3 (abstract A4). Type of surgical procedure
Type of operations HOSPITAL DEPT p
n % n %
Total thyroidectomy with dissection of
lymph node central neck compartment
9 8.8 12 2.4 0.004
Total thyroidectomy 68 66.7 283 56.6 0.06
Subtotal thyroidectomy 6 5.9 130 26 <0.001
Bilateral subtotal thyroidectomy 0 0 6 1,2 NS
Lobectomy 18 17.6 63 12.6 NS
Secondary thyroid operations 1 1 3 0.6 NS
Palliative thyroid resection 0 0 3 0.6 NS
TOTAL 102 100 500 100
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versity Medical College in Cracow by the same surgeons in the years
2007-2008. The groups of patients were then compared and analysed
statistically. Statistical analysis involved comparing the groups with re-
spect to specific diagnostic criteria, using the chi-square test and Fisher's
exact test for categorized discrete variables, and the Mann-Whitney U
and Kruskal-Wallis tests for continuous variables. The Student-t test was
employed to calculate probability and confidence interval.
Results
Between 2010 and 2015, 102 operations for goitre were performed
in the Department of Short-stay Surgery of the St. John Grande Hos-
pital of Brothers Hospitallers, Cracow. The comparison group con-
sisted of the material of 500 patients operated for thyroid disease in
the Department of Endocrine Surgery JU CM (DEPT) in the years
2007 – 2008. The groups were similar with respect to age and sex.
The duration of post-operative stay in the first group (HOSPITAL) was
1.9 days ± 0.3, as compared with 3.8 days ± 1.36 in the second group
(DEPT) (p < 0.001) (Table 1).
In assessing patients for potential short-stay surgery, those for over-
active goitre were less frequently qualified than those with thyroid
inflammation (p < 0.001). There were no significant differences in the
other types of goitre (Table 2).
We must note that the cancers were at a less advanced stage in pa-
tients operated for thyroid cancer under the short-stay regime, than
those in the second group. The extent of the operation, and operative
technique were similar between the two groups studied (Table 3).
Complications arising were also compared, and these were less fre-
quent in operative patients in the first (hospital) group (7.8% vs
17.8%) (p = 0.012).
Conclusion
Short-stay surgical treatment of thyroid conditions in specialist cen-
tres is possible and is as safe as conventional-term treatment, with
no increase in the frequency of postoperative complications.
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Radioiodine therapy (RIT) is an important method of treatment of
hyperthyroidism. Two different approaches to RIT are represented
with regard to dosage of radioiodine (131I): individual dose calcula-
tion based on a detailed dosimetry and the administration of fixed
doses of 131I aimed at the hypothyroidism as the final outcome. As
shown by the statistics on huge numbers of patients followed for
decades after RIT, even using meticulous calculation of the activity
of therapeutic 131I, hypothyroidism is very common – it is found in
approx. 30% of patients with toxic nodular goitre and even in 80%
of patients with Graves' disease. The risk of hypothyroidism in-
creases with each passing year after RIT at a rate of approximately
3-5% per year.
RIT effect depends on many unmodifiable factors, for example thy-
roid mass, clinical form of hyperthyroidism, hormonal status etc.
Several studies have demonstrated reduced efficacy of RIT in pa-
tients with lower TSH concentrations, higher thyroxine concentra-
tions and higher TRAb titres. There is, however, a number of factors
that can be modified to obtain a better result of RIT. The efficacy of
RIT is primarily dependent on the kinetics of iodine in the thyroid
gland. It can be followed using dosimetric measurements. A spot
measurement of thyroid iodine uptake after 24 h (IU24) may not re-
flect the actual exposure of the gland to beta radiation. High values
of IU24 are associated with poorer treatment effect, as these pa-
tients present a rapid iodine turnover and 131I is retained in the thy-
roid for a relatively short time. Iodine kinetics can be improved by
low-iodine diet. Reducing the supply of iodine by the reduction of
food intake based on fish, seafood and marine plants, as well as
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of iodine by 20-30%. Longer elimination of iodine is not recom-
mended because of possible side effects, e.g. hyponatremia. In the
case of very low IU24 values, lithium salts can improve the effect of
RIT. Although lithium is not responsible for the increase of iodine
uptake by the thyroid gland, it does increase the retention time of
iodine in the thyroid. The use of approx. 1 g of lithium carbonate
per day for 5-14 days resulted in an increase of absorbed dose and
a reduction of cases with the therapy failure. More and more often
rhTSH is used to stimulate iodine uptake. A single injection of
rhTSH causes usually 2-4-fold increase in the 131I uptake. Due to
stimulation of the thyroid hormone release, this method is mainly
used in the treatment of non-toxic nodular goitre. Stimulation with
rhTSH frequently causes side effects like pain at the base of the
neck and temporary increase of the thyroid volume.
Antithyroid drugs used before, during and after RIT adversely affect
the final outcome of the treatment (number of patients achieving
euthyroid or hypothyroid status after RIT is lower). This is con-
nected with their impact on iodine uptake, their immunomodula-
tory action and radioprotective effect in the thyrocyte. This effect is
more pronounced in the case of propylthiouracil than methimazole.
Therefore, while preparing the patient to RIT, following expert rec-
ommendations should be followed: refrain from the use of these
drugs in case of slight hyperthyroidism, in more severe cases prefer
methimazole over PTU and withdraw the drug for 2-7 days (methi-
mazole) or 2-3 weeks (propylthiouracil) before RIT. If necessary, an
antithyroid drug can be resumed after RIT, optimally approx. 1 week
after the administration of 131I.
Corticosteroids, amiodarone and iodine contrast agents should be
named among the drugs that adversely affect the effect of RIT.
Through their cytoprotective and immunosuppressive effect, corti-
costeroids reduce the radiosensitivity of the thyroid cells. Therefore,
for the prevention of Graves orbitopathy, corticosteroids should be
introduced a few days after RIT. Although the contrast agents con-
tain large amounts of iodine (approx. 30 g of organic iodine and
5 mg of iodide in an average dose), urinary iodine excretion returns
to normal as early as after 1-2 months after injection. Amiodarone
treatment is regarded as an absolute contraindication to RIT. How-
ever, as demonstrated by retrospective studies in our centre, RIT
used in an experimental setting in such patients even at very low
IU24 led to normalization of amiodarone-induced hyperthyroidism
in a few months.
RIT often leads to hypothyroidism. Nevertheless, in accordance with
the ALARA rule, we should strive to achieve a therapeutic effect
using the lowest possible radionuclide activity. Thus, taking the fac-
tors described above into account while preparing the patient to
RIT will allow to optimize the treatment effect and to reduce the
exposure of the patient and the environment (including ourselves)
to ionizing radiation.
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Thyroid orbitopathy (TO), the most frequent extrathyroidal manifest-
ation of Graves’ disease (GD) occurs in approximately 2 per 10 000
population per year and in 25%–60% of patients with GD in clinically
relevant form. Progression of mild to moderate-to-severe TO may
occur in up to 15% of subjects and no predictors are available to pre-
dict worsening at a first clinical examination. Therefore the manage-
ment of mild TO and prevention of the aggravation is one of the
most common problem in practical endocrinology.
Mild TO is usually diagnosed basing on soft tissue involvement (con-
junctival and eyelid oedema and congestion) and proptosis < 3 mm
above the upper limit. However it must be noted, that eye muscle in-
volvement may be often underestimated due to low sensitivity of
generally used motility tests. Despite often discrete manifestations at
clinical examination diplopia is the principal symptom influencing pa-
tients’ quality of life (QoL) and his work ability. Moreover, as subject-
ive factor as the impact of symptoms on patient’s everyday life and
work must be considered. Therefore in big proportion of patient the
grading of TO and a subsequent decision on implementation the im-
munosuppressive treatment is based on patient’s self-assessment.
Strict metabolic control with the avoidance of hypothyroidism is a prin-
cipal element of the treatment of thyrotoxicosis in GD patients. Changes
in thyroid status may negatively influence TO. Therefore, evaluation of
thyroid function ought to be frequent (every 6–8 weeks or even more
often) during the first phases of treatment (or after changing the daily
dose of the ATD) and periodical (every 3–4 months) thereafter.
Treatment methods for hyperthyroidism [ATDs, radioiodine (RAI),
thyroidectomy] per se seem to be capable to affect the course of
TO and the choice of method is still a challenging dilemma. Ran-
domized trials showed that TO grew more often after RAI than after
thyroidectomy or ATDs .
The influence of RAI on TO are uncertain, due to the limited number
of controlled studies. Steroid prophylaxis is recommended in patients
on RAI treatment, if mild and active TO pre-exists. Because TO may
also appear for the first time after RAI treatment, it is generally worth
wide to consider the pros and cons of steroid use also in GD patients
with risk factors as male gander, age > 60 yrs, smoking and high
TRab titre. Steroid prophylaxis can be performed with very low doses
of prednisone (0.2 mg/kg body weight), given 1 day after RAI ther-
apy, gradually tapered down and stopped after 6 weeks. In subject
with risk factors for the RAI-associated TO progression, doubled both
doses of prednisone and time of treatment should be implemented.
Tabaco smoking markedly increases the risk of developing TO and
aggravate it is course. Smokers are 4-fold more prone to develop eye
symptoms and as much as 27-times more often experience the se-
vere stage. Smokers respond less well to treatment with steroids or
radiotherapy then non-smokers (15% vs. 85%). The efficacy of help-
ing patients stop smoking is very low: opportunistic advice from doc-
tor only 2%. Therefore all GD patient should be honestly informed
about the risk and nicotine replacement therapy may be considered.
GD subjects are at high risk of dry eye symptom due to mechanical fac-
tors, hormonal disturbance, autoimmunological process and side effects
of commonly used drugs. Orbital discomfort (at rest or with gaze) must
be distinguished from ocular surface irritation from exposure. It may be
also hypothesized the inflammation at the eye surface via proinflamma-
tory cytokines may induce inflammation in retrobulbar space. Therefore
all subjects with OT and may be the majority of GD patients, should be
advised to consistently use local measures. Artificial tear drops or gels
(administered 4-6 times daily – in the morning, by meals and at bed
time) and lubricant ointments prior to slipping can reduce surface symp-
toms and improve quality of life. The use of preservative-free drops can
help to avoid allergic reactions, epithelial toxicity and conjunctival in-
flammation by preservatives and particularly benzalkonium chloride.
Thyroid Research 2016, 9(Suppl 1):6 Page 6 of 24Non-ophthalmologists often forget, that such simple solutions can
have a significant impact on TO symptoms.
Antioxidant therapy in TO has been used for ca. 30 years but re-
ported results are extremely divergent. Hoverer randomized, placebo
control study conducted by EUGOGO showed selenium (but not
pentoxyfylline) treatment within 6 months induced significant im-
provement in eye status and QoL during 12 month follow up. There-
fore selenium supplementation (200 μg daily) is recommended for
patients with mild TO and may be advised for GD subjects free of TO
but with risk factors.
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Thyroid dysfunctions in pregnancy are relatively common and they
have a negative impact on the health of the mother and her offspring.
The physiological changes during pregnancy influence the thyroid
function, thus the existing guidelines recommend the necessity to pre-
pare the trimester-specific thyroid hormone reference ranges for each
medical centre and analytical method used. In case of a lack of such
TSH reference ranges the following ones are generally accepted: I trim:
0.1-2.5 mU/L, II and III trim. 0.2-3.0 (ATA, ES) – 3.5 mU/L (ETA).
While discussing the thyroid illness in pregnant women, it has to be
underlined that despite the well-informed guidelines and expert
work there are areas of substantial uncertainty. Among others the
most important questions are: how to define the SH during preg-
nancy, can the maternal SH adversely affect the foetus and the
mother and how to assess/balance the risk and benefit of any inter-
vention. The endpoint of the clinical studies are the pregnancy com-
plications and foetal cognitive development as possible, well-known
hypothyroidism-related disturbances. The dilemmas in relation to the
normal TSH reference range followed by the SH definition in preg-
nancy result from the differences caused by variations in assays,
population-specific factors such as ethnicity, dietary habits, iodine
status, BMI. These dilemmas can also be caused by the fact that the
even slight abnormalities in thyroid function are potentially un-
favourable factors associated with child outcome. Maternal thyroid
hormones (TH) are the only source of TH for foetus especially in the
first half of pregnancy.
What is normal? – this is the most frequent question. According to
the International Federation of Clinical Chemistry the reference inter-
vals have to be based on the 2.5th and 97.5th percentile of the re-
spective population with an optimal iodine intake in case of thyroid
hormone ranges assessment. In meta-analysis based on the 14 well-performed studies (in which TSH and FT4 were calculated in accord-
ance with the international guidelines and the sufficient number of
pregnant women with negative thyroid antibodies were enrolled to
the studies), Medici et al. [1] showed that there are essential differ-
ences in upper TSH reference value during early pregnancy world-
wide and in 90% of cases TSH upper limit value exceeds the
recommended TSH level (2.63-4.68 mU/L). The results of the Gener-
ation R study [2], a large cohort study, suggest that the diagnosis of
the SH should be undertaken when TSH >4.04 mU/l and normal FT4
(10.4-22.0 pmol/L). Bestwick et al. [3] suggest using multiple of the
median (MoM) values to overcome the limitation connected with
TSH and TH assessment during pregnancy. TSH and FT4 (MoMs) sig-
nificantly reduced the difference between UK and Italian samples
compared with conventional units, which were also confirmed by
Medici et al. in the above, cited work in different populations [1].
In the face of the above facts, there are critical questions whether
our pregnant women are treated in euthyroidism and whether the
treatment of the euthyroid pregnant women has a negative effect
on pregnancy course and foetus.
There are some new clinical data confirming that even subclinical
thyroid dysfunction in pregnancy increases the risk of mother and
child adverse outcomes. Among others, Liu et al. [4], in prospective
cohort study of 3315 women screened, showed that the women with
SCH were at an increased risk of miscarriage between four and eight
gestational weeks but statistical significance was achieved only if
TSH ≥5.22 mU/L. Women with a combination of SCH and TAI were
found to were at the highest risk of miscarriage and, for that, at earl-
ier gestational ages.
In conclusion, it should be stated, that the current available data con-
cerning the upper TSH limit value in pregnancy, safe for mother and
her offspring, could probably be higher than previously thought. It
requires further clinical studies, however, thyroid related research in
pregnant population is difficult to conduct.
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There has been a dynamic increase in detectability of differentiated
thyroid cancer (DTC) in recent years. This increase is mainly due to
detection of small foci of papillary carcinoma, which is characterized
by very good prognosis. Increased morbidity does not result in in-
creased mortality. Currently the management of the DTC patient dic-
tates a lifelong oncologic surveillance due to recurrences or distant
metastases observed even many years after the onset of the disease.
Diagnostics and treatment can be a significant burden for the pa-
tients. Thyroid surgery involves the risk of hypoparathyroidism and
damage of the recurrent laryngeal nerve. The frequency of surgical
complications depends on surgeon's experience and scope of the
surgery. The risk of postsurgical hypoparathyroidism significantly in-
creases with the central compartment lymph node dissection and
when the surgery is performed by an inexperienced surgeon (less
than 10 surgeries a year). Another burden for the patient is using the
131I therapy. It has been indicated that using an isotope with the ac-
tivity above 100 mCi increases the risk of leukaemia. Another danger
is the increased risk of salivary gland cancer or fertility impairment.
The way to avoid the above complications is using the 131I with pos-
sibly lowest activity and stimulating the 131I uptake with recombinant
TSH instead of LT4 withdrawal. It has also been indicated that using
Thyrogen decreases the 131I radiotoxicity by 30-50%, while maintain-
ing the high effectiveness of ablation. Discontinuation of the 131I
therapy is also essential in groups of very low recurrence risk, where
benefits of such therapy have not been indicated. The usage of sup-
pressive LT4 doses increases the risk of atrial fibrillation and has an
influence on bone mineral density decrease in postmenopausal
women. Periodic oncologic follow-up which include stimulated Tg
measurement or a whole–body scan, what is further associated with
physical and psychological burden. Adjusting the treatment and
monitoring the disease is necessary in case of poor disease outcome.
There are ongoing studies on several risk stratification systems. Sev-
enth edition of the TNM system according to AJCC/UICC is com-
monly used. This system correlates very well with the risk of fatal
outcome, however, it does not allow a good differentiation of high
risk recurrent/persistent disease patients. Using the system is recom-
mended worldwide, as it allows keeping the epidemiological regis-
ters and monitoring the changes in DTC epidemiology. Stratification
systems recommended by ATA and ETA are also used to assess the
risk of disease recurrence, taking into account assessment of the
histological type and surgical radicality of the procedure. In 2015,
new ATA recommendations advise taking into account the number
and extent of the lymph node involvement (>5 and the size of me-
tastasis in a node >0.2 cm and clinically identified nodes) as factors
which affect the prognosis. Other factors which affect the prognosis
are the degree of the extrathyroidal extension (microscopic or exten-
sive) and the degree of vascular invasion in follicular thyroid cancer.
Attempts are being made to use molecular factors (BRAF, TERT) as
prognostic elements, but the data concerning this subject is incon-
clusive. In 2010, Tuttle et al. suggested a delayed risk stratification
system (DRS), applied 2 years after finishing the initial treatment. The
system assumes effectiveness of the therapy as a predictor. Patients,
who respond very well to the treatment (Tg/LT4 < 0.2, Tg/stimulated
<2.0, no evidence of disease at ultrasound examination and a whole-
body scan), constitute the low-risk group. Whereas, patients with bio-
chemically persistent disease (Tg/LT4 > 1.0, Tg/stimulated >10.0, in-
creasing anti-Tg serum) or structurally persistent (disease seen in
imaging and physical examinations) constitute the high-risk group.
The group with ambiguous response is composed of patients with
serum Tg/stimulated >2.0 < 10, stable or decreasing anti-Tg levels,
nonspecific changes in imaging. Studies carried out by several teamsconfirm high effectiveness of the above stratification system in pre-
dicting the outcome. It is recommended to use the delayed risk
stratification system to personalize the LT4 treatment by adjusting
the suppression level to the risk as well as by modifying the intensity
and method of the oncologic follow-up. Using the DRS system will
allow many patients to avoid negative outcomes of the LT4 suppres-
sive therapy as well as mentally and physically burdensome periodic
follow-up of possible disease remission. At the same time, it will
bring significant savings for the health care budget.
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Background
One billion people worldwide are characterized by vitamin D defi-
ciency. Vitamin D deficiency is also prevalent in subjects with Hashi-
moto`s thyroiditis. It was proved that serum 25(OH)D levels in these
patients are lower than in healthy individuals. This observation sug-
gests that vitamin D deficiency may play an important role in the de-
velopment of thyroiditis. Several clinical trials have shown that
supplementation of vitamin D may reduce the incidence of rheumatoid
arthritis, multiple sclerosis and type 1 diabetes. In experimental studies it
was proved that 1,25(OH)2D3 may prevent Hashimoto`s disease, however
the mechanisms of this impact has so far not been explained. It was also
reported that administration of vitamin D together with anti-thyroid
drugs or thyroid hormones suppresses the autoimmune reaction and re-
duces serum levels of thyroid autoantibodies. The discovery of the pres-
ence of vitamin D receptors in the thyroid gland probably indicates that
vitamin D plays a role in regulation of thyroid function. The association
of hypothyroidism with higher body mass is commonly known. Also the
state of vitamin D supply is inversely correlated with obesity.
Aims
To determine whether there is a correlation between the concentra-
tion of 25(OH)D3, body weight and TSH level in patients with Hashi-
moto's thyroiditis.
Materials and methods
Covered 65 patients [55 F; 10 M] aged 20-86 years [mean 50.5 ±
20.3], hospitalized in our department between 2013-2015. Analysis of
clinical picture and laboratory studies. Serum TSH levels were mea-
sured with CLIA and 25(OH)D3 with ECLIA assays.
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Vitamin D3 deficiency <20 ng/mL was found in 45 [40 F; 5 M] =
69.2% of patients. In 15.4% [n = 10], vitamin D3 concentrations
ranged from 20 to 30 ng/mL [hypovitaminosis], while in another
15.4% vitamin D3 levels were within the normal range [>30 ng/
mL]. Depending on the concentration of 25(OH)D3 the patients
were divided into 4 groups: group 1 covered 10 people [6 F; 4 M]
with 25(OH)D3 concentration >30 ng/mL [average value 41.2 ±
9.2]; group 2 – 10 patients [9 F; 1 M] with 25(OH)D3 level between
20 and 30 ng/mL [average 22.5 ± 2.6]; group 3 – 22 people [20 F;
2 M] with 25(OH)D3 value between 10-20 ng/mL [mean 14.4 ±
2.8]; group 4 – 23 patients [19 F; 4 M] with 25(OH)D3 concentra-
tion <10 ng/mL [mean 6.8 ± 1.9]. BMI for groups 1 to 4 was
respectively: 25.0 ± 5.6 kg/m2; 23.5 ± 4.4 kg/m2; 27.1 ± 6.1 kg/m2
and 27.6 ± 4.9 kg/m2. BMI in groups 3 and 4 was significantly
higher (p <0.001) than in group 1. Mean TSH levels were respect-
ively: in group 1 – 1.4 ± 1.4 [range from 0.1 to 3.9] mIU/L; in group
2 – 1.5 ± 1.2 [0.1-4.2] mIU/L; in group 3 – 10.4 ± 22.9 [0.1-87.0]
mIU/L; in group 4 – 3.6 ± 4.8 [0.73-19.3] mIU/L. TSH levels differed
between group 1 and group 4 statistically significantly [p < 0.001].
Additionally, all patients were divided into two major groups:
group 1 = 20 people [15 F; 5 M] with 25(OH)D3 > 20 ng/mL and
group 2 = 45 patients [40 F; 5 M] with 25(OH)D3 < 20 ng/mL. Aver-
age 25(OH)D3 concentrations were respectively: 31.84 ± 11.65 ng/
mL in group 1 and 11.05 ± 4.52 ng/mL in group 2 (p < 0.001), TSH
levels: 1.47 ± 1.31 mIU/L and 6.9 ± 16.5 mIU/L (p < 0.001), and BMI:
24.27 ± 5.15 kg/m2 and 27.37 ± 5.48 kg/m2 (p < 0.001). The age of
patients in both groups was respectively: 41.55 ± 19.24 and 54.69
± 5.48 years (p < 0.001).
Conclusions
Patients with Hashimoto's thyroiditis and 25(OH)D3 concentrations
below 20 ng/mL are characterized by higher body weight and higher
TSH levels. Our results suggest that vitamin D3 supplementation may
have a positive effect on the proper control of hypothyroidism and
body weight in patients with Hashimoto's disease.
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The aim of the lecture is to present a summary on main aspects re-
lated to complications resulting from the use of thionamides for
treatment of thyrotoxicosis, including methimazole (MMI), carbima-
zole (CMZ) and propylothouracil (PTU). Though benign complications,
such allergic rash, urticaria or pruritus are common, main issues re-
lated to adverse effects of antithyroid drugs include hepatotoxicity,
birth defects as well as agranulocytosis.
Methimazole/carbimazole-induced hepatotoxicity usually develops in
the first few weeks of drug consumption with an estimated incidence
of 0.1-0.2%. Hepatic abnormalities associated with methimazole are
typical of a cholestatic process. In contrast, PTU-induced hepatotox-
icity is of hepatocellular type in most cases, and hence is considered
to be more serious. The frequency of PTU-related severe liver dam-
age is approximately 0.1% based on the available data [1, 2]. In rare
instances PTU administration might be associated with development
of ANCA-related vasculitis [3].
Up till recently PTU was considered the drug of choice during preg-
nancy, because of small risk of MMI/CMZ embryopathy (such as apla-
sia cutis), though these recommendations had been contested.
Realization of consequences of PTU-induced hepatotoxicity, including
liver failure [2] resulted in change of current recommendations, par-
ticularly pertaining to pregnancy. In particular, current recommenda-
tions (e.g. Thyroid 2011;21:1081–1125) advise administration of PTU
only in the first trimester of pregnancy, with subsequent change into
MMI/CBZ. Recent studies, however, have cast doubt on the validity of
these recommendations. First of all, thyrotoxicosis per se seems to be
associated with an increased risk of birth defects [4]. Furthermore,
both MMI/CBZ and PTU seem to associated with a similar increase in
the frequency of birth defects, though different type of defects seem
to occur in women taking MMI/CBZ versus those taking PTU [4, 5].
There are also no available data showing any benefit of switching
from MMI/CBZ to PTU in the first trimester of pregnancy in terms of
a risk of birth defects [5]. Hence in the recent commentary [6], the
British authors recommend against switching to PTU in the first tri-
mester of pregnancy, and recommend continuation of the lowest
possible doses of MMI/CBZ.
Agranulocytosis (and in rare cases even more severe complications such
as pancytopaenia or aplastic anaemia) remains the most feared compli-
cation of thionamide use. It should be mentioned that mild leukopenia
is commonly observed in thyrotoxicosis, particularly in Graves’ disease.
Incidence of agranulocytosis is considered to be around 3-4 cases per
10000 patients. According to the recent large retrospective study from
Japan [7], agranulocytosis developed within 90 days after starting ATD
therapy (84.5% out of 754 cases of agranulocytosis), and more com-
monly in females. Methimazole dose administered at the onset of
agranulocytosis was 25.2 ± 12.8 mg/day (mean ± SD).
There is, however, no universal agreement as to the best strategy to
detect agranulocytosis, and in particular in relation to the usefulness
of routine monitoring of white cell counts (WCC). There is a possibil-
ity that there are at least two patterns of development of agranulo-
cytosis. The first, being much more common, involves a sudden
autoimmune attack with rapid development of agranulocytosis, even
within 24-48 hours. Indeed Nakamura et al. [7], demonstrated cases
of agranulocytosis that developed suddenly, despite a normal WCC
that had been observed even at one to two days prior to detection
of agranulocytosis. Yet, there is also another pattern that is associ-
ated with a gradual decrease in WCC, that can be potentially de-
tected by routine WCC monitoring. Hence, Japanese authors [7]
Fig. 1 (abstract A10). An example of information card on the risk of
agranulocytosis (from Belchetz and Hammond, Mosby’s Colour Atlas
and Text of Diabetes and Endocrinology, Mosby 2003, page 255)
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the past 5 years at Kuma Hospital, where about 1500 new Graves’ pa-
tients start antithyroid drugs treatment annually, and found that nearly
half of the patients were diagnosed with asymptomatic conditions by
routine monitoring of granulocyte counts.”
On the other hand, British and Australian endocrinologists [8, 9], en-
tirely disagree with such strategy, and recommend immediate checks
of WCC only in cases of pyrexia, severe sore throat or an overt infec-
tion. Furthermore, some authors directly criticize routine WCC moni-
toring, and state [8] that: “Agranulocytosis can occur precipitously and
without warning so routine white counts may engender a false sense of
security.” The British authors recommend a written information to be
given to each patient receiving antithyroid drugs (together with a
standard printed letter sent to General Practitioner or other health
professionals), and strongly recommend that WCC checks should be
done in primary care, rather than in specialist clinics. An example of
such an information card is provided below (Fig. 1, from reference nr
8). Given my own personal experience, as well as difficulties to follow
Japanese recommendations in Polish settings (for instance methima-
zole package insert in Japan includes a strong warning to check
blood counts every 2 weeks for the first 2 months of therapy), I have
adopted the British strategy in my personal medical practice.
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Currently, the most important clinical issue for a practicing endocrin-
ologist is to answer the question whether the detection of thyroid
nodule/nodules during physical examination or thyroid focal lesion/
lesions in the ultrasound (US) scan provides the basis for referring
the patient for surgery. The role of fine-needle aspiration biopsy
(FNAB) in preoperative diagnostics of such cases is undeniable.
The fine-needle aspiration biopsy performance is recommended for
each case of: 1) a palpable nodule corresponding to focal lesion with
diameter of 5 mm or more, revealed during US examination, 2) an
impalpable lesion with a diameter of 10 mm and more, visualised in
US examination, 3) a lesion with suspicious US features, suggesting
the malignancy (microcalcifications, “taller-than-wide” shape, in-
creased irregular, chaotic central blood flows, hypoechogenicity, un-
even thickness or absence of halo, solid composition (echostructure),
the size greater than 3 cm in diameter, poorly defined and/or irregu-
lar margin, the rapid enlargement of lesion, as well as the presence
of lymph nodes invasion.
Many years of personal experience allows us to say that the best way
of conducting disease management is simultaneous careful consider-
ation of both US findings and FNAB result, categorised according to
The Bethesda System of Reporting Thyroid Cytology (TBSRTC) [1,2].
In addition to US data, one should account several disturbing clinical
signs and symptoms, such as occurrence of hoarseness, dysphagia or
pain which result from the presence of the thyroid tumour of firm
consistency (Table 4). Also of importance is information on inherited
diseases, with particular stress on multiple endocrine neoplasia 2A
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(FMTC) or familial non-MTC (FNMTC) in 1st degree relatives, as well
as history of neck, head, chest or whole body irradiation - especially
if it relates to the childhood. Another high risk factor of thyroid can-
cer that absolutely qualifies for further diagnostic investigation is pa-
tients’ age - under 20 and over 60 years. Furthermore, male sex is
regarded as a risk factor for malignancy of thyroid lesions. The coex-
istence of essential “disturbing clinical signs and symptoms”, men-
tioned above, provide additional data indicating an increased risk of
the malignant neoplastic disease.
As regards evaluation of ultrasound image pattern (US pattern risk),
we have created the scoring system based on our own experience.
For easier memorising the list of US features which should be
assessed during US examination of thyroid nodules/focal lesions, we
propose respective mnemonics [2,3].
Mnemonics are made up of the first letters of the names of these
characteristics. The occurrence of calcifications (C) – especially micro-
calcifications, orientation (O) - “taller-than-wide”, when the antero-
posterior diameter of a nodule is longer than its transverse diameter
on a transverse or longitudinal plane, abnormal Doppler patterns (D),
and echogenicity (E) - hypoechogenicity is awarded 1 point for each
of these features. The absence of the regular "halo" (H), solid echos-
tructure (E), the lesion largeness > of 3.0 cm (L), blurred margins (M)
are associated with granting of 0.5 points for each of the features.
Despite all the above characteristics, the attention should particularly
be paid to the coexistence of augmentation (A) – the rapid enlarge-
ment of nodules and/or of focal lesions, accompanied by the pres-
ence of pathologically altered lymph nodes (L). The presence of
these last two signs/symptoms out of ten (10) characteristics, is of
crucial significance as it indicates a serious suspicion of the malig-
nancy. Occurrence of each of these two features is associated with
granting of 3 points. Our system, based on assigning the points to
each US feature, is an attempt to evaluate risk stratification what – in
turn – can help to select the optimal clinical decisions. The principle
of assessment is to add points, which will allow classification of the
lesions to particular groups of a different risk of malignancy (Table 5).
However, in order to so happened, one should – as mentioned be-
fore – pay attention to the presence of other essential “disturbing
clinical signs and symptoms” (Table 4).
It is to be stressed that introduction of the scoring system for “the
disturbing symptoms and signs” is useless, because their assessment
can be simply achieved by applying common sense. In other words,
the occurrence of almost all of these symptoms by itself requires the
execution of all possible diagnostic tests, followed by treatment
implementation.
Having proposed our own point system, as a solution of the
problem being - according to us - the most objective, I would like
to recall how three other research groups coped with the prob-
lem in question.
Chilean authors, Horvath et al. [4], have developed a system of
reporting ultrascan examination results of the thyroid nodules, strati-
fying risk of cancer during the clinical management (Thyroid Imaging
Reporting And Data System – TIRADS), taking as an example the
model of reporting data from US studies of the breast (BIRADS).
First, the authors [4] reviewed US findings of 362 thyroid nodules to
define and specify their characteristics and establish US patterns. The
following variables were considered: echostructure, echogenicity,
shape, orientation, acoustic transmission, borders, surface, presence
or absence of a capsule, calcifications, and vascularization.
Next, the authors prospectively correlated the FNAB results of an-
other set of 500 nodules with the defined US patterns and generated
a TIRADS group classification (TIRADS 1–6 for general thyroid path-
ology and TIRADS 2–6 for nodules).
The following categories were established: TIRADS1 – normal thyroid
gland; TIRADS2 – benign conditions (0% malignancy); TIRADS3 –
probably benign nodules (<5% malignancy); TIRADS4 – suspicious
nodules (5–80% malignancy rate): 4a (malignancy 5-10%), 4b (malig-
nancy 10-80%) was optional; TIRADS5 – probably malignant nodules
(malignancy >80%); TIRADS6 – category included biopsy proven ma-
lignant nodules [4].Park et al. [5] reported the results of their study in which they pre-
sented own system of data, reporting US features of the thyroid
cancer.
The authors proposed an equation to predict the probability of ma-
lignancy in thyroid nodules based on 12 features of thyroid nodules,
as noted on US.
This equation, and the stratification of its results into categories,
should be useful in reporting the findings of US for thyroid nodules
and in guiding management decisions.
Final regression analysis of the selected findings allowed the elaboration
of a regression equation to generate logit of malignant thyroid nodule
(z): z = -2.862 + 0.581X1 - 0.481X2 - 1.435X3 + 1.178X4 + 1.405X5 +
0.700X6 + 0.460X7 + 0.648X8 - 1.715X9 + 0.463X10 + 1.964X11 + 1.739X12.
The formula for the probability of malignancy of a thyroid nodule is
as follows: Pus = 1/(1 + e-z), where: Pus - the probability of malignancy,
as calculated by logistic regression using ultrasound features of the
nodules; e - mathematical constant (e = 2.71828 . . .) [5].
Twelve independent variables were used in the equation in order to
calculate the logit of malignant thyroid nodule: X1 - shape: taller = 1,
wider = 0; X2 - perinodular halo: presence = 1, absence = 0; X3 - well
circumscribed: presence = 1, absence = 0; X4 - microlobulation: pres-
ence = 1, absence = 0; X5 - infiltrative margin: presence = 1, absence = 0;
X6 - marked hypoechoic: presence = 1, absence = 0; X7 - hypoechoic:
presence = 1, absence = 0; X8 - homogeneous echotexture: presence =
1, absence = 0; X9 - mainly cystic: presence = 1, absence = 0; X10 - solid:
presence = 1, absence = 0; X11 - microcalcification: existence = 1, ab-
sence = 0; and X12 - lymph node: abnormal = 1, normal = 0 [3].
Using this regression equation, Pus value of nodules classified as be-
nign ones, was 0.07 to 0.23 with 95% CI, and 0.04 to 0.50 with 99%
CI. Pus of nodules classified as malignant was 0.37 to 0.90 with 95%
CI and 0.07 to 0.97 with 99% CI.
After calculating the Pus for each nodule, the authors stratified its dis-
tribution for each nodule and summarized the representative US
findings to make the analysis applicable to a clinical setting: TUS 1
(Pus – 0-0.07) - inadequate cases, TUS 2 (Pus – 0.08-0.23) - benign,
TUS 3 (Pus – 0.24-0.50) - indeterminate, TUS 4 (Pus – 0.51-0.90) – sus-
piciously malignant, TUS 5 (Pus – 0.91-1.0) – malignant, 99% CI [5].
The term “echotexture” requires explanation: it is defined as
homogenous or mixed echogenicity, the latter due to the aggre-
gation of multiple microcystic components intervening the solid
component.
Korean authors divided US images of thyroid nodules into three cat-
egories: 1) nodules suspected of malignancy; 2) probably benign
nodules; 3) indeterminate nodules [6].
The following features are characteristic for malignant processes: 1)
“a taller-than-wide shape”; 2) a spiculated margin; 3) marked hypoe-
chogenicity; 4) microcalcifications and macrocalcifications. The pres-
ence of at least one of these findings for malignancy defines a
nodule as a suspicious malignant nodule [6].
The shape of a nodule (“taller-than-wide”, AP > TR diameter when im-
aged in the axial plane) has gained diagnostic importance for the dif-
ferentiation of benign and malignant nodules since this was first
described in a study by Kim et al. [7]. Also, in our studies, the shape
was the strongest prognostic US feature of malignancy [1,2,3].
In contrast, a simple cyst, a predominantly cystic or cystic nodule
with reverberating artifacts and a nodule with a spongiform appear-
ance (especially with intervening isoechoic parenchyma) are defined
as probably benign nodules [6].
Indeterminate nodules include nodules having US findings with nei-
ther malignant nor clearly benign characteristics. The US findings for
an indeterminate nodule include: 1) isoechogenicity, hypoechogeni-
city, and hyperechogenicity, 2) an ovoid-to-round or irregular shape,
3) a smooth or ill-defined margin, 4) a rim calcification [4].
At the end of this presentation, I would like to quote a systematic
review and meta-analysis of 31 studies from the years 1985 to
2012 (18 288 nodules), carried out by Brito et al. [8]. The results
have led the authors to the following conclusions: 1) low - to
moderate-quality evidence suggests that individual ultrasound
features are not accurate predictors of thyroid cancer, 2) two
features - cystic content and spongiform appearance, however,
Table 4 (abstract A11). Two mnemonics for easier memorising the list
of “disturbing signs and symptoms” that require inquisitive intense
diagnostics, regardless of TBSRTC category and US pattern [2]
HARM HASH
H Heredity H Hoarseness
A Age A Ache
R Radiation S Swallow
M Male H Hardness
Table 5 (abstract A11). The scoring system of US features (patterns)
assessed in thyroid nodules/focal lesions. Low risk US pattern – 0 < 3
points; intermediate risk US pattern –≥ 3 < 7 points; high risk US
pattern - ≥ 7 points [3]
CODE (each feature – 1 point)




HELM (each feature – 0.5 point)




AL (each feature – 3 points)
A Augmentation Max. no. of points – 6
L Lymph node involvement
Thyroid Research 2016, 9(Suppl 1):6 Page 11 of 24might predict benign nodules. However, this observation has very
limited use in clinical practice, because of the rarity, especially of
the latter characteristics.
Remonti et al. [9] - on the basis of a systematic review and meta-
analysis of 52 studies retrieved by July 2012 (12 786 nodules) - con-
cluded that there is no isolated US feature capable of predicting ma-
lignancy in thyroid nodules with acceptable diagnostic accuracy.
However, the presence of some US features, such as: 1) a microcalci-
fications, 2) a taller than wide shape, 3) irregular margins, 4) central
vascularization, 5) or absence of elasticity probably will identify nod-
ules with an increased risk for malignancy.
In summary, the main goal of the preoperative diagnostics of thyroid
tumours is the quickest and the most accurate selection of cases
which should be surgically treated. Procedures proposed by us ap-
pear to be the simplest approach to the problem in question.
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Background
Autoimmune thyroiditis (AIT) is a complex disease, which results from
the interaction of both genetic predisposition and environmental
triggers. Many different loci have been associated with increased sus-
ceptibility to AIT: both immunoregulatory (e.g. HLA class II, CTLA-4,
PTPN22) and thyroid specific (Tg) genes variants. Among environmen-
tal factors some viral and bacterial infections, medications and
inadequate micronutrients supply are believed to play a role. Selen-
ium - a trace element built into the active centre of large protein
family known as selenoproteins – is essential for protection against
oxidative stress, for immune system balance maintenance and thy-
roid hormones synthesis and metabolism. Its deficiency is considered
to be one of the factors underlying AIT etiopathogenesis.
Fig. 2 (abstract A12). Comparison of serum selenium concentration
between European populations with AIT and results obtained in
our study
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The aim of our study was: 1) to assess the serum selenium concentra-
tion in patients with AIT and healthy volunteers in Polish population
living in the Wielkopolska region, 2) to compare our results with data
on selenium supply in other European populations.
Materials and methods
Forty seven euthyroid patients (41 women, 6 men) with AIT treated
with L-thyroxine in dose of 1 μg/kg bw to 2 μg/kg bw was included
in the study. Elevated TPO-Ab and/or Tg-Ab concentration and ab-
normalities typical for AIT found in the thyroid ultrasound were the
criteria of AIT diagnosis, the coexistence of other diseases was ap-
plied as exclusion criteria. A control group consisted of 36 (24
women, 12 men) healthy, age and sex-matched volunteers. Patients
with pathologies of the thyroid gland and other autoimmune, aller-
gic, inflammatory or neoplastic diseases were excluded from the con-
trols. The concentrations of TSH, TPO-Ab and Tg-Ab were determined
by ELISA method. Serum selenium concentration in both groups was
measured by electrothermal atomic absorption spectrometry (normal
range 70-150 μg/L). The Mann-Whitney U test and Fisher exact test
were used for statistical analysis (Statistica, StatSoft, Inc. 2011).
Results
The median serum Se concentration was 62.9 μg/L (ranging from
2.2 μg/L to 224.0 μg/L) in the patients group and 39.8 μg/L (ranging
from 1.8 μg/L to 161.2 μg/L) in the control group (p = 0.029). A de-
creased selenium concentration was observed in 58% of the patients
and in 72% of the controls (p = 0.29). There was no statistically sig-
nificant difference (p > 0.05) in serum Se status in AIT group compar-
ing to the results of other Polish, German, Austrian, Dutch and Greek
populations with AIT, except from one Italian study, where signifi-
cantly higher values were observed (p < 0.001)
Conclusion
In these preliminary results selenium deficiency is observed in the
Polish population in both AIT patients and in the controls. Selenium
supplementation should be considered in the deficiency state with
further assessment of its results.
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Background
Osteoprotegerin (OPG) a member of the TNF receptor family, has
been identified as a regulator of bone resorption because it acts as
a decoy receptor by competing with the RANK ligand (RANKL recep-
tor activator of nuclear factor kappa B ligand) for binding to the re-
ceptor activator of NF-κB (RANK) to exert an inhibitory effect on
osteoclastogenesis, osteoclast differentiation and bone remodelling
regulation. OPG is produced by a variety of tissues, including bone,
the cardiovascular and immune system. Hitherto, it has been re-
ported that the OPG/RANK/RANKL molecular triad plays an import-
ant role in several diseases, such as osteoporosis and cardiovascular
diseases. OPG deficient mice (OPG-/-) develop severe osteoporosis
and vascular calcifications. An increase in serum OPG is suggested
to be a biomarker of the presence and severity of coronary heart
disease and a risk factor for cardiovascular mortality. The physio-
logical role of OPG, beyond the regulatory function of bone turn-
over, is the inhibition of cell apoptosis induced by inflammatory
processes. OPG/RANK/RANKL are produced by variety of tissues in-
cluding epithelial and mesenchymal cells. However, the role of
RANKL/OPG in thyroid pathophysiology remains unclear. Anyway, it
is known that hormonal disorders of the thyroid gland can be re-
lated to bone tissue disorders as well.
Aims
The aim was to identify the role of OPG in the context of the thyroid
gland and thyroid disorders.
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PubMed database was searched for relevant articles from 2002 up to
May 2015.
Results
It has been proven that OPG is produced in the thyroid gland by thy-
roid follicular cells and this synthesis may be modulated by thyroid
autoimmunity. OPG mRNA levels are three times more abundant in sur-
gical thyroid specimens of Graves’ disease compared with other thyroid
disorders, OPG concentrations are higher in Graves' disease patients
than in toxic nodular goitre ones and euthyroid subjects with Hashimo-
to's thyroiditis have increased levels of OPG compared to healthy con-
trols. In the human thyroid follicular cell line XTC and in primary human
thyroid follicular cells, OPG mRNA levels and protein secretion are up-
regulated by TSH, IL-1β and TNFα. Neutralizing antibodies to OPG
reverse the inhibitory effect of TSH on osteoclast differentiation eviden-
cing that the TSH effect is at least in part mediated by elevated OPG.
The association between thyroid function and OPG concentration has
been shown. As well in hyperthyroidism as in subclinical and overt
hypothyroidism, an increase in serum OPG levels has been reported
which can be reversed / normalized by treating the diseases (anti-thy-
roid treatment or substitutive therapy). In thyrotoxicosis, an imbalance
between bone resorption and formation is observed that results in
bone loss and an increased risk for osteoporotic fractures. The low
serum TSH, observed in thyroidectomized subjects on L-thyroxine ther-
apy, is connected to an increase of bone turnover in postmenopausal
women and men that is associated with a rise in OPG and a decrease
of serum RANKL levels. Elevated concentrations of OPG in patients with
hyperthyroidism are in relation to thyroid hormone excess and high
bone turnover. The change of OPG levels is also associated with PTH
concentration. Medical treatment of hyperthyroidism normalizes thy-
roid hormones and serum OPG levels in temporal relationship with the
normalization of bone metabolism markers. Thus, it has been sug-
gested that OPG may be involved in the cross-talking between thyroid
function and bone metabolism in hyperthyroidism. Moreover, in a
group of patients on suppressive hormone thyroid therapy with differ-
entiated thyroid cancer, it has been proven that elevated levels of OPG
(as well as changes in OPG/RANK/RANKL system), besides bone degrad-
ation, may influence on increased risk of cardiovascular diseases. It is
also well known that hypothyroidism is associated with an increased
risk for cardiovascular disease, impaired endothelial function and a rise
in serum OPG is reported to connect to the severity of coronary heart
disease and cardiovascular mortality. In hypothyroid patients, in whom
elevated OPG concentrations are observed, during the course of the
treatment, the absolute changes in OPG levels show a significant correl-
ation not only with the changes in TSH but also with the changes in
endothelium-dependent arterial dilation and plasma von Willebrand
factor (a vascular injury marker). OPG levels are significantly higher in
hypothyroid patients with silent myocardial ischaemia compared to
hypothyroid subjects without vascular disease and in this group serum
OPG is associated with flow-mediated endothelium-dependent arterial
dilation. Even in euthyroid patients with Hashimoto's thyroiditis, serum
OPG decreases dramatically after 6 months regular aerobic exercise
training and is correlated with endotelium-dependent arterial dilata-
tion. Therefore, it has been postulated that elevated serum OPG may
be involved in the development of vascular dysfunction in hypothyroid
patients. Concerning the role of OPG in carcinogenesis, it has been de-
scribed that OPG/RANK/RANKL are expressed in the neoplasmatic thy-
roid gland - papillary and medullary carcinomas and macrovesicular
adenomas by follicular cells and malignant parafollicular cells as well as
in metastatic lymph node microenvironment. On thyroid cancer cells
in vitro, OPG inhibits TRAIL-induced apoptosis and may promote
tumour cell survival. Although OPG and TRAIL expression in benign
and malignant tissues does not differ significantly, the expression of
RANK protein appears to be suppressed and RANKL expression is in-
creased in malignant thyroid tissue. Thus, this triad is hypothesized to
play a role during pathogenesis of follicular and parafollicular tumours,
as well as in the metastatic process of carcinoma cells to lymph nodes.
Conclusions
Undoubtedly, OPG plays a significant role in thyroid disorders. There-
fore, further accurate assessment of the OPG relevance and its con-
centration in patients with thyroid diseases is needed.Declarations




Availability of data and materials
Not applicable
Competing interests








MEN 1 syndrome, MEN 2 syndrome or neuroendocrine lung tumour
with metastases to the thyroid and pituitary glands in 57-year-old
patient treated in Department of Endocrinology in Szczecin
Elzbieta Andrysiak-Mamos, Elzbieta Sowinska-Przepiera, Ewa Zochowska,
Bartosz Kiedrowicz, Agnieszka Kazmierczyk-Puchalska, Anhelli Syrenicz
Department of Endocrinology, Metabolic and Internal Diseases,
Pomeranian Medical University, Szczecin, Poland
Correspondence: Anhelli Syrenicz
Thyroid Research 2016, 9(Suppl 1):A14
Background
In spite of current recommendations neuroendocrine tumours may
cause diagnostic and therapeutic challenge. Frequently, patients find
their way to the referral centres in the advanced stage of the disease.
Case Report
64-year-old male patient was sent to Department of Endocrinology
in 2013 because of liver metastases of neuroendocrine tumour. He
was operated in 2006 for the left lung tumour (typical carcinoid). For
a few years he complained about flushing and diarrhoea. Since 2014
abdominal pain appeared and both abdominal ultrasound and CT
showed multiple hepatic lesions described as metastases. Chest CT
revealed neither local tumour recurrence nor right lung metastases.
Histopathological examination of hepatic lesions confirmed neuroendo-
crine tumour with Ki67 from 17 to 31%. Somatostatin receptor scintig-
raphy reported increased expression of the receptors in liver and
thoracic vertebrae defining NET metastases. High levels of chromogra-
nin, 5-HIAA, calcitonin, CEA and AFP were detected. Thyroid ultrasonog-
raphy showed a few lesions up to 10 mm in size. Medullary thyroid
cancer was suspected on the basis of FNAB result and high serum calci-
tonin level and total thyroidectomy was performed. In histopathological
examination there were multiple foci of neuroendocrine tumour with
Ki67 from 7 to 22% and negative calcitonin immunoreactivity so the
diagnosis of medullary thyroid cancer was ruled out. Subsequently
histopathological diagnosis of a lung tumour from 2006 was verified as
G2 (Ki67 – 12%), T3N1M0. The patient has been treated for 8 months
with somatostatin analogues with good effect. Because of abnormal pi-
tuitary hormones levels, pituitary MRI was performed and showed a
macroadenoma, which in histopathological analysis turned out to be a
neuroendocrine tumour metastasis.
Conclusions
1. High serum levels of calcitonin and suspicion of medullary thyroid
cancer in FNAB of thyroid lesions in patient with NET do not rule out
thyroid metastases of NET. 2. Patients with NET need a follow-up
with thyroid ultrasonography seeking for metastases.
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Oxidative stress promotes aging and contributes to multiple diseases,
such as cancer and neurodegeneration. The thyroid tissue is an ex-
cellent model to study oxidative stress as active hydrogen peroxide
(H2O2) production is required for thyroid hormone synthesis. Besides
being a substrate in hormone synthesis H2O2 is a source of reactive
oxygen species (ROS). Several studies revealed increased oxidative
stress and oxidative DNA damage in thyroid tissue.
In presented research we were investigating the possible involve-
ment of the hMTH1 protein, the major mammalian detoxifier of the
oxidized DNA precursor, 8-oxo-dGTP, in the pathogenesis of differ-
entiated thyroid cancer. Studies were performed on human thyroid
tissues (cancerous and healthy), as well as normal (NTHY-ori 3-1),
papillary (TPC1 and BCPAP) and follicular (FTC133) cancer thyroid
cells using immunohistochemical, immunocytochemical, Q-RT-PCR,
Western blot and flow cytometry techniques.
In agreement with earlier observations from other cancer types im-
munohistochemical analysis revealed hMTH1 protein overexpres-
sion in the thyroid tumours compared to normal thyroid tissues.
Analysis of signalling pathways activated upon silencing of hMTH1
gene expression revealed activation of MAPK signalling in NTHY
cells. In addition, in NTHY cells increased Akt signalling was ob-
served, whereas it was decreased in two of the cancer cell lines
studied (FTC133 and TPC1). Although hMTH1 gene knockdown had
no influence on distribution of cell-cycle phases and apoptotic cell
number up-regulation of p21 protein was observed in p53-
proficient cell lines, NTHY and TPC1. Finally, phenotypic analysis re-
vealed only minor influence of hMTH1 gene silencing on prolifera-
tion rate and migration ability of NTHY and TPC1 cells.
Our data suggest that unexpectedly, differentiated thyroid cancer
cells seem to tolerate hMTH1 down-regulation quite well, as evi-
denced by limited influence of hMTH1 silencing on their survival,
proliferation, apoptosis and distribution of cell cycle phases, in spite
of dependence of most of cancer cells types on hMTH1 protein
expression.
Presented research was supported by Foundation for Polish Science
PARENT/BRIDGE programme co-financed from European Union funds
under the Innovative Economy Operational Programme 2007-2013.
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Thyroid cancer is the most frequent endocrine neoplasia. Malignant
transformation of nodular goitre (NG) can lead to the development
of follicular adenoma (FA) that can progress into: papillary thyroid
carcinoma (PTC) or thyroid follicular cancer (FTC). Ambiguous diagno-
sis as a result of preoperative differential diagnosis of thyroid nod-
ules using fine needle aspiration biopsy (FNAB) is a significant clinical
problem. It is important to search for new biomarkers differentiating
follicular-cell derived thyroid tumours (FCDT), especially in case of
FNAB with underdetermined cytology (Bethesda III-IV) or with
„neoplasma folliculare” diagnosis.
Aims
Analysis of expression levels of selected tumour suppressor genes
(TSG): ARHI, CDKN2A, KCNQ1, CDH1 and PTEN in follicular tumour le-
sions FA, FTC and FVPTC (in tumour tissue examined postopera-
tively), and thyroid nodule biopsies taken during surgery. Assessment
of usefulness of selected TSGs examination in patients with the "fol-
licular neoplasm" in FNAB diagnosis.
Materials and methods
Biological material was obtained from 56 patients (aged 16 to
76 years) with preoperative diagnosis PTC/„neoplasma folliculare”.
Histopathological classification: NG, n = 23; FA, n = 6; PTC, n = 22; FTC,
n = 5. RNA was isolated from FNAB and cancer tissue (both collected
during total thyroidectomy) using Universal RNA Purification Kit
(Eurx, Poland). Qualitative and quantitative analysis of RNA was per-
formed spectrophotometrically (BioPhotometer, Eppendorf). QPCR
analysis was performed using Taq Man Low Density Arrays, TaqMan
Array Micro Fluidic Card in 7900 HT Fast Real-Time PCR System (Ap-
plied Biosystems, USA). Relative gene expression (RQ) level of each
TSG was assessed using ΔΔCT method.
Results
Gene expression level of CDKN2A, KCNQ1 and CDH1 genes was at
comparable level in tumour tissue and material from biopsies in the
whole group, and groups of diagnosis (PTC, FTC, NG). Differences in
expression levels of ARHI and PTEN genes were observed between
cancer tissue and FNAB material, and in histopathological groups.
ARHI and PTEN expression was significantly elevated in FNAB material
when compared to cancer. There was no correlation of elevated
gene expression with clinical or histopathological features.
Conclusions
Molecular analysis of the material obtained from intraoperative fine
needle aspiration biopsy or FNAB washes (in case of sufficient volume
of material) allows the assessment of the relative expression of sev-
eral genes. Analysis of expression of CDKN2A, KCNQ1 and CDH1,
due to the comparable level of expression in tissues and biopsies,
may have diagnostic significance and in the future may contribute
to the improvement of differential thyroid lesion diagnosis carried
out using FNAB.
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Thyroid hormones (HT), T3 and T4 play a key role in the control
of metabolism, through their contribution in the regulation of
many crucial physiological processes in both children and adults.
T3 and T4 are involved in the control of energy balance, growth
and differentiation, brain development and function, circulation,
osmotic and temperature control as well as in the regulation of
other hormonal systems. The metabolism of the thyroid gland is
precisely controlled by the active interaction between the
hypothalamus-pituitary and thyroid gland maintaining a narrow
range of normal T3 and T4 levels. Any disruption in the synthesis,
secretion, transport and extrathyroidal T3/T4 metabolism can
have an adverse effect. Disturbances in endocrine systems can be
triggered by many factors such as diet, diseases or exposure to
environmental chemicals and pollutants.
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animal models, wildlife observations and human studies strongly
suggests that many of the chemicals commonly found in the envir-
onment, have a negative effect on the thyroid gland and peripheral
metabolism of thyroid hormones. Among thyroid disruptors (TDCs,
thyroid disrupting chemicals) are industrial chemicals (polychlorinated
biphenyls (PCBs), bisphenol A, flame retardants, phthalates, perchlo-
rate and others), pesticides, and compounds used in the personal
care products and cosmetics (among other UV-filters). TDCs can
affect many steps of thyroid physiology and regulation from iodide
uptake through thyroid hormones biosynthesis, transport to periph-
eral tissues, cellular uptake, peripheral deiodination, receptor activa-
tion, and finally their hepatic degradation and elimination. Hence,
significantly more attention should be given to the identification of
chemical compounds produced by humans, disrupting the function
of the thyroid gland, which exert early and long-term effects on the
adults and offspring and TDCs should be more widely noticed and
recognized by the endocrinologists.
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Background
Radioiodine therapy is one of the radical and relatively safe methods
of treatment of hyperthyroidism.
Aims
The aim of the study was to assess the efficacy of radioiodine ther-
apy in patients with hyperthyroidism, depending on the diagnosed
thyroid disease, termed as thyroid hormones concentrations, mea-
sured 12 months after radioiodine administration.
Material and methods
The analysis of hormonal and imaging findings, including isotopic re-
sults, in 1032 patients (865 F, 167 M) treated in the Department of
Nuclear Medicine and in the Endocrinology Department, in Medical
University of Lublin, during the eight-year period.
Results
In the studied group of patients, 484 subjects (85.33% of F) aged
55.42 ± 14.17 years had autonomous adenoma (AA), 366 subjects
(80.60% of F) aged 46.68 ± 13.50 years - Graves' disease (GD), and in
182 participants (86.26% of F) aged 58.21 ± 12.96 years toxic nodular
goitre (TNG) was diagnosed. In patients with AA: 80.79% achieved
euthyroidism (81.60% of F with AA/76.05% of M with AA), 3.3% -
hypothyroidism (3.39% of F with AA/2.82% of M with AA), and in
15.91% of patients (15.01% of F with AA/21.13% of M with AA)
hyperthyroidism was observed; the efficacy of radioiodine therapy
was estimated to be 84.10% (F – 84.99%; M – 78.87%). In patients
with GD, euthyroidism was found in 24.32% (25.42% of F with GD/
19.72% of M with GD), hypothyroidism - in 39.34% (39.32% of F with
GD/39.44% of M with GD), and hyperthyroidism - in 36.34% of pa-
tients (35.26% of F with GD/40.84% of M with GD); the efficacy of
radioiodine therapy was estimated to be 63.66% (F – 64.75%; M –
59.15%). Whereas, in subjects with TNG: 69.23% of patients achieved
euthyroidism (66.88% of F with TNG/84.00% of M with TNG), 8.79% -
hypothyroidism (8.92% of F with TNG/8.00% of M with TNG), and
21.98% had still hyperthyroidism (24.20% of F with TNG/8.00% of M
with TNG); the efficacy of radioiodine therapy was estimated to be
78.02% (F – 75.80%; M – 92.00%).
Conclusions
Radioiodine therapy was the most effective in patients with AA and
the least efficacy was achieved in GD subjects. Males responded bet-
ter to treatment if the diagnosis of TNG had been made.A19
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Background
Autoimmune polyglandular syndromes (APS type 1, 2 and 3) are a
group of diseases characterized by the coexistence of autoimmunologi-
cal disorders of endocrine glands, other organs and systems as well.
Aims
The aim of the study was to determine the prevalence of Graves'
disease and Hashimoto's thyroiditis as components of APS and their
coexistence with other autoimmunological disorders.
Material and methods
Retrospective analysis of clinical symptoms as well as hormonal and
imaging findings in 89 patients (70 F, 19 M) aged 50.0 ± 14.8 years,
treated in the Endocrinology Department, Medical University of Lublin,
between 2003 and 2015.
Results
Autoimmunological thyroid disease (ATD) was observed in 84.27% of
subjects with APS: 100% with APS1, 86.36% with APS2, 82.26% with
APS3. Graves' disease was diagnosed in 25.84% of patients with APS
(19 F, 4 M): 13.64% with APS2 and 32.26% with APS3. In APS2, in 1
subject - type 1 diabetes and asthma were also found. In APS 3,
Graves' disease coexisted the most often with: type 1 diabetes (60%),
vitiligo (15%), alopecia areata (10%), Addison-Biermer anaemia (10%),
miasthenia gravis (5%) and autoimmune hepatitis (5%). Hashimoto's
thyroiditis was diagnosed in 58.43% of patients with APS (45 F, 7 M):
100% with APS1, 72.73% with APS2, 50% with APS3. In APS1, type 1
diabetes, vitiligo and alopecia areata were found as well. In APS2,
Hashimoto's thyroiditis coexisted the most often with: type 1 dia-
betes, sarcoidosis, asthma and vitiligo. In APS3, besides Hashimoto's
thyroiditis, type 1 diabetes (77.42%), vitiligo (22.58%), Addison-
Biermer anaemia (16.13%), psoriasis (12.9%), alopecia areata (6.45%)
and celiac disease, colitis ulcerosa, sarcoidosis, rheumatoid arthritis
and asthma (3.23%) were observed.
Conclusions
Autoimmunological thyroid diseases are common components of
APS, however Graves' disease occurs half as often as Hashimoto's
thyroiditis. The coexistence of ATD and type 1 diabetes, vitiligo and
Addison-Biermer anaemia are the most prevalent.
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Radioiodine therapy may cause progression or development of Grave’s
orbitopathy in 15-25% of patients. Moderate dose of glucocorticoids
may protect orbital activation, however the optimal dose and duration
of preventive steroids therapy is not established.
The aim of the study was to compare the effectiveness and safety of
oral and intravenous glucocorticoids.
Eighty seven radioiodine treated Graves’ patients with mild orbitopathy,
clinical activity score < 3/7, 72% (63/87) of them smokers, received
prophylactic steroids, started at radiotherapy day. Sixty patients re-
ceived oral prednisone, starting dose 30 mg or 20 mg daily for four
weeks and then gradually reduced within 10 weeks, total dose
1200 mg and 790 mg respectively, and 27 patients received
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dose 1000 mg. Patients were assessed before and during 1-24 month
after radioiodine therapy.
Graves’ orbitopathy progression evaluated using the clinical activity
score was the primary outcome, side effects of steroid were the sec-
ondary outcome.
Graves’ orbitopathy progression and the indication for massive sys-
temic corticotherapy was observed in both groups, in 8.3% (5/60)
prednisone and in 7.4% (2/27) methylprednisolone patients. Activa-
tion occurred at smokers only independently of another risk factors
such elevated serum T3 and TRAb levels or recurrent radioiodine
therapy. The inconstant side effects including increase in body
weight, elevated blood pressure, insomnia, and acne were noticed in
prednisone group only. One diabetic patient from methylpredniso-
lone group needed a marked increase of daily insulin dose.
Prophylactic oral or intravenous glucocorticoids are equally effective
in prevention of Graves’ orbitopathy activation after radioiodine ther-
apy but the intravenous method is safer.
A21
Gluten-free diet and Hashimoto's thyroiditis
Roman Junik
Chair and Division of Endocrinology and Diabetology, L. Rydygier Collegium
Medicum in Bydgoszcz, Bydgoszcz, Poland; Nicolaus Copernicus University
in Torun, Torun, Poland
Thyroid Research 2016, 9(Suppl 1):A21
Euthyroid patients but with a high titre of autoantibodies, which con-
sequently endocrinologist refused treatment, they feel abandoned
by the official medicine. They start to walk to different paramedics,
apply a variety of diets, including the paleo-diet or just gluten-free.
Autoimmune thyroid diseases co-exist (not just of Hashimoto's thy-
roiditis but Graves' disease as well) and celiac disease stems from a
common genetic predisposition (e.g. HLA-DQ2 and DQ8 haplotypes
and other, e.g. CTLA-4). Autoimmune diseases of the thyroid gland
and celiac disease is relatively rare: 4.8% (Collin), 3.3% (Sategna-
Guidetti), 5.4% (Cuocco), 3.4% (Berti), 4.4% (Meloni), etc. Generally, it
is considered that it is 2-5% of cases.
In the opposite direction it works a little differently, because in stud-
ied patients with celiac disease, frequency of accompanying auto-
immune thyroid diseases was a bit higher: 6% (Reunala and Collin),
5.4% (Collin), and 14% (Counsell). Anti-TPO autoantibodies have been
found in 29.7% (Veluzzi) and all types of antithyroid autoantibodies
together were present in 41% (Kowalska, but this was children’s
population). Perhaps this relatively high percentage of antithyroid
auto-antibodies in patients with celiac disease is confused with the
inverse situation, that is the presence of celiac disease (2-5%) in pa-
tients with autoimmune thyroiditis. Another problem is the fact that
symptomatic celiac disease in adults is rare, the disease is insidious.
Celiac disease can be resolved by performing a titre of IgA class anti-
bodies: antiendomysial (EmA) and anti-tissue transglutaminase (anti-
tTG).
You can also measure other antibodies. The gold standard is a biopsy
of the mucous membrane of the proximal segment of the small in-
testine (Grzymislawski). It was confirmed that a gluten-free diet in
patients with celiac disease with particular inflammation of Hashi-
moto could cause the disappearance of antithyroid autoantibodies
(Ventura), but Mainardi has not found such a relationship. Sategna-
Guideti concluded that a gluten-free diet causes relief of subclinical
hypothyroidism in patients with celiac disease, while Cooper or
Viljamaa such compounds are not observed. Patients with celiac
disease and hypothyroidism under the influence of a gluten-free
diet reduced the severity of primary hypothyroidism, and took the
lower dose of thyroxine. It was found that a gluten-free diet is likely
to be made as soon as possible, in order to reduce the risk of auto-
immune thyroid inflammation join.
Summing up: the problem of a gluten-free diet affects patients with
celiac disease, this diet is required. In the case of patients with auto-
immune thyroiditis a gluten-free diet should take 2-5% of people, be-
cause so many suffer from celiac disease. If it is so make sense toforce the remaining 95-98% of patients with Hashimoto's thyroiditis
without celiac disease, a gluten-free diet for? Of course, in the case
of suspicion of the presence of celiac disease follow a gluten-free
diet and screening apply only in the case of the diagnosis of celiac
disease.
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Critical illness is defined as any life-threatening conditions requiring
maintaining vital organ functions in order to avoid the upcoming
death. Without modern intensive medical care the survival rate of
critically ill patients is impossible. Critical illness is an extreme (the
final) form of strenuous exercise. Biological reactions appearing in re-
sponse to this condition are triggered immediately and on a larger,
than in other clinical situations, scale. Stress response (critical illness)
involves the reaction of the endocrine system (and also referred to
as "the endocrine adaptation") and metabolic response. As a result of
intensive medical care the survival rate of patients in states previ-
ously fatal has been increased, but currently more the patients
"enter" in the chronic phase of critical illness, and requires a many
weeks support/sustain the organ functions despite the removal of
factors, which initiate the critical status. The lecture covers the data
from recent years on the impact of serious non-thyroidal diseases on
the function of the hypothalamic-pituitary-thyroid (HPT) axis and thy-
roid hormones metabolism that contributed to determining a patho-
mechanism of NTIS (non-thyroidal illness syndrome). The differences
between acute and chronic phase of critical illness and between sys-
temic inflammatory response syndrome (SIRS) (as sepsis) and condi-
tions other than SIRS are discussed. Practical use: assessment the
clinical status of critically ill patients, interpretation of laboratory
tests, therapeutic treatment correction, endocrinological consulta-
tions in Intensive Care Unit.
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There are three mechanisms in which thyroid hormones exert effect
on the cardiovascular system:
1. Modulation of activity of nuclear receptors (triiodothyronine – T3).
2. Regulation of ion flow through the plasma membrane and
within the cytoplasm (T3 and thyroxine – T4).
3. Altering responsiveness to sympathetic stimulation.
Hyperthyroidism results in increased heart rate (HR), left ventricular
contractility and stroke volume (SV). This, in turn, according to Frank-
Starling law (CI [cardiac index] = SV x HR), increases the CI value and
greatly contributes to the development of hypertension. Thyrotoxi-
cosis also produces vasodilatation which increases systolic pressure
and decreases diastolic pressure. Blood pressure amplitude rise pre-
sents itself as pulsus celer et altus sign.
Cardiovascular symptoms of thyrotoxicosis can by relieved by beta-
blocker (BB) therapy. In the course of BB treatment we observe heart
rate and blood pressure normalization as well as alleviation of sym-
pathetic overstimulation symptoms. However, as BB are not a
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half life time or receptor and organ selectivity should be taken into
consideration before the initiation of treatment. Their specific proper-
ties should also be considered – e.g. Nebivolol increases nitric oxide
synthesis and reduces the oxidative stress which is of utmost import-
ance in patients with diabetes and advanced atherosclerosis.
Hypothyroidism, on the other hand, results in CI and SV decrease. In-
creased vascular resistance and pulsus parvus et tardus sign, results of
diastolic heart dysfunction, are as well observed. Impaired vasodilata-
tion also serves as a main mechanism in diastolic blood pressure rise.
Hence, the antihypertensive drugs used in hypothyroid patients
should aim at dilating blood vessels and improving left ventricular
diastolic function. Sino-atrial suppressors, as well as drugs promoting
peripheral oedema are not advised. Angiotensin converting enzyme
inhibitors (ACEI) and calcium-channel blockers seem to be the drugs
of choice. However, similarly to BB, before treatment initiation their
characteristics, as well as patient's comorbidities must be considered.
Again, extra care should be given to the drug selection in patients
with atherosclerosis. Only ACEI with well-documented favourable
clinical outcome should be utilized in this group (e.g. long-acting
Zofenopril containing sulphydryl group). Lecarnidipine, on the other
hand, shows highest lipophilicity and lowest rate (<1%) of peripheral
oedema among calcium-channel blockers which do not affect the
pacemaker activity in the sino-atrial node.
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Background
Thyroid diseases are the most common endocrine disorders.
Although their detection rate is increasing, a considerable num-
ber of the above-mentioned conditions remain undetected. As
population-wide screening tests would incur insupportable costs,
there is a great need for highly sensitive and cost effective diag-
nostic tools. 99mTc-MIBI is a radiopharmaceutical commonly used
in the scintigraphic assessment of myocardial perfusion. It also
accumulates in cancer cells, but may be as well used in the diag-
nostics of other, benign thyroid conditions.
Aims
The aim of the study was to assess the clinical significance of the
focal 99mTc-MIBI-avid thyroid lesions discovered incidentally during
myocardial perfusion scintigraphy and to evaluate the utility of myo-
cardial perfusion scintigraphy in the diagnosis of thyroid pathologies.
We also aimed to develop an algorithm for the diagnosis of inciden-
tal thyroid lesions based on photon count number within defined re-
gions of interest (ROI).
Material and methods
Focal 99mTc-MIBI uptake in the thyroid was observed in 88/1041 pa-
tients referred to the Department of Nuclear Medicine of Military In-
stitute of Medicine in Warsaw for 99mTc-MIBI myocardial perfusion
scintigraphy between 14.01.2009 and 31.10.2011. To include a pa-
tient in the study, 99mTc-MIBI-avid thyroid lesion must have been re-
ported by two nuclear medicine specialists. Quantitative analysis of
thyroid scans included determining count number within ROI drawn
over lesion as well as over two reference points: the contralateral
thyroid lobe and lungs. All patients also underwent physical examin-
ation, thyroid ultrasound and laboratory tests measuring TSH, FT3,
FT4, anti-TPO, TRAb, CEA, calcitonin, total calcium and phosphate
levels. Based on the ultrasound results, selected patients were re-
ferred for fine-needle aspiration biopsy of thyroid lesions.
All patients participating in the study have signed a written consent
form. The study has been reviewed and approved by the Bioethics
Committee of the Military Institute of Medicine in Warsaw.Results
Among 88 patients with focal 99mTc-MIBI uptake thyroid disease was
confirmed in 68 (77.2%) cases. Additional tests revealed: multinodular
goitre (40 patients, 45.4%), solitary thyroid nodules (21 patients,
23.9%), 3 of which were autonomous, and autoimmune thyroid disor-
ders (23 patients, 26.1%), among which were 7 cases of Graves' dis-
ease and 16 cases of Hashimoto's thyroiditis. Two patients (2.3%)
were diagnosed with papillary thyroid carcinoma. ROI count number
did not differ significantly between the group of patients with and
without thyroid disease. In consequence, we were unable to develop
a diagnostic algorithm based on photon count number within the
ROIs. The gathered data also suggested that the quantitative evalu-
ation of thyroid is not superior to the visual assessment.
Conclusions
1. Myocardial perfusion scintigraphy proved a valuable imaging
method for detecting thyroid diseases. Thyroid pathologies
diagnosed in patients with incidental focal 99mTc-MIBI uptake
comprised thyroid nodules (74%), Hashimoto's disease (18%),
Graves' disease (8%) and papillary thyroid cancer (2%) were the
most common.
2. Quantitative and visual method of thyroid image interpretation
did not yield significant differences in the accuracy of thyroid
diseases diagnosis. In consequence, we were unable to create a
diagnostic algorithm based on photon count number within ROI.
3. Thyroid assessment should be considered a standard procedure
during stress myocardial perfusion scintigraphy as it shows
usefulness in thyroid pathology diagnosis.
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The increased level of thyroid antibodies is observed in at least
15% of women of childbearing age. In turn, the prevalence of
hypothyroidism, especially of its subclinical form during preconcep-
tion and gestational state, is estimated at the level of 10-15% or it
is possibly higher. Hypothyroid patients on L-thyroxine replacement
should be carefully monitored to keep TSH and thyroid hormones
in recommended ranges before conception and during pregnancy.
Untreated hypothyrodism has serious consequences, with de-
creased fertility being repeatedly documented. Whereas both overt
and subclinical hypothyrodism constitute unquestionable indica-
tions for replacement therapy with L-thyroxine in most women of
childbearing age, the cut-off values of thyroid tests still remain the
point of debate. According to current recommendations, the esti-
mated TSH upper limit of 2.5 mIU/L relates only to women planning
pregnancy, pregnant and lactating women.
The aim of the study was to evaluate relationship between lipid per-
oxidation (LPO; index of oxidative damage to membrane lipids) and
thyroid tests and other parameters, which may be affected by thy-
roid dysfunction, in euthyroid women of childbearing age.
Ninety nine (99) women, aged 18-48 years, without thyroid dysfunc-
tion (TSH 0.27–4.2 mIU/L, normal FT4 and FT3), were enrolled. Blood
concentrations of malondialdehyde + 4-hydroxyalkenals (LPO index)
were measured spectrophotometrically. Thyroid tests (TSH, FT4, FT3),
thyroid antibodies and other laboratory parameters [cholesterol, HDL
cholesterol (HDLC), LDL cholesterol, HDLC/cholesterol ratio, triglycer-
ides, glucose, CRP, iron) were measured with standard methods.
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women with TSH < 2.5 mIU/L. Positive correlation was fund between
TSH concentration and LPO level. In the univariate regression analysis,
blood LPO level did constitute the only factor associated with TSH ≥ 2.5
mIU/L. Abnormal HDLC/cholesterol ratio occurred more frequently in
subjects with TSH ≥ 2.5 mIU/L. Additionally, positive correlation was
found between LPO level and triglyceride concentration, whereas nega-
tive correlation was found between LPO level and HDLC concentration
or HDL/cholesterol ratio.
In euthyroid women of childbearing age, TSH ≥ 2.5 mIU/L is associated
with higher LPO and less favourable lipid profile, which suggests that
TSH of less than 2.5 mIU/L should be maintain in the whole group of
women of childbearing age.
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Background
Primary thyroid lymphoma is a rare thyroid neoplasm (about 1%),
which develops often (70-80%) on the basis of Hashimoto’s thyroid-
itis. The most common thyroid cancer is the papillary cancer (>80%).
Its follicular variant has nuclear morphological features and biological
character of the papillary thyroid cancer but creates follicular
structures.
Case report
68-year-old female patient, clinically and biochemically euthyroid,
after I-131 radioiodine therapy for toxic nodular goitre was sent to
the Endocrinology Outpatient Clinic with FDG PET/CT test result, per-
formed as oncologic control after the ovarian cancer surgery per-
formed in 2012. The patient had no complaints and there were no
abnormalities in physical examination. Anti-thyroid autoantibodies ti-
tres were in normal range. FDG PET/CT revealed 9 mm hypodense le-
sion in the left lobe of the thyroid gland with SUV 5.62, which may
correlate to adenoma, however malignancy could not be excluded.
Thyroid ultrasonography showed in the right lobe a few, very small
nodules and one bigger 10 x 9 x 7 mm solid hypoechoic lesion - with
benign result of FNAB. It revealed also 17 x 12 x 8 mm diffuse hypoe-
choic area with increased flow in power Doppler on the border of
isthmus and the left lobe and cytological and cytometric tests con-
firmed B-cell lymphoma. Oncology committee qualified the patient
to surgery. Thyroidectomy was performed and histopathological
examination revealed follicular variant of papillary thyroid cancer in
9 mm lesion in the right lobe and follicular lymphoma in 19 mm
white infiltration on the border of isthmus and the left lobe. Cur-
rently, the patient receives R-CHOP chemotherapy.
Discussion
Microcarcinoma is very often an accidental finding in the thyroid
gland removed because of other reasons than preoperatively con-
firmed cancer (25% or more).
Even though thyroid lymphoma belongs to rare tumours of thyroid
gland, it needs to be kept in mind not only in patients with Hashimo-
to’s thyroiditis. In 80% of the cases in ultrasound images it presents
as single hypoechoic lesion, sometimes almost anechoic, diffuse, with
increased colour Doppler blood flow.
Conclusion
A patient after radioiodine treatment of toxic nodular goitre needs a
regular endocrine follow-up including thyroid ultrasound and in case
of finding new lesions FNAB is necessary.Consent for publication
The authors acquired written informed consent from the patient.
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Background
Molecular tests are used more commonly in qualifying a nodular
goitre for the surgery, apart from the thyroid ultrasound and fine
needle aspiration biopsy (FNAB), as on the basis of cytological exam-
ination conclusive diagnosis may not be always established. The re-
search data indicate that in 10-15% of the FNAB not enough
specimen is obtained to make a diagnosis and about 20% of biopsy
analysis is in the range of cytological results, which demand postop-
erative histopathological verification.
Aims
Evaluate the incidence of BRAF T1799A mutation and RASSF1A pro-
moter methylation level in cellular specimens derived from FNAB of
thyroid nodules.
Materials and methods
The study population consisted of 80 women aged 18 to 65 years.
Hormonal tests ruled out hyper- and hypothyroidism. Using autoanti-
bodies and ultrasound autoimmune process was excluded. The study
material was genomic DNA isolated from peripheral blood and thy-
roid bioptates. BRAF mutation was analyzed by standard methods of
real-time amplification detection (real-time PCR) with the use of spe-
cific starters surrounding the mutated site. Pyrosequencing was used
for the evaluation of RASSF1A methylation level.
Results
A significant positive correlation was demonstrated between mean
methylation of four CpG islands of RASSF1A gene and thyroid tumour
volume and its largest diameter (p < 0.05). BRAF T1799A mutation
was found in 6/80 subjects (7.5%). In 5/6 mutation carriers benign
nature of the thyroid nodules was confirmed by FNAB of the lesions,
while non-diagnostic specimen was obtained from 1 subject but
histopathological post-operative assessment diagnosed papillary thy-
roid cancer.
Conclusion
The results of genetic tests reported in our study indicate that the
presence of BRAF mutation or higher RASSF1A methylation levels in
FNAB cytology specimens of benign lesions may be useful in the as-
sessment of oncological risk. Molecular tests may facilitate preopera-
tive diagnosis of thyroid nodules and qualifying for surgery or
conservative treatment.
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The first case of central hyperthyroidism due to thyrotropinoma
[TSH-oma] was reported in 1960 and since then more than 450
cases of TSH-oma have been published. The prevalence of these
tumours is about one case per million, and they account for about
0.5–3.0% of all pituitary adenomas. Most patients are diagnosed in
the fifth-sixth decade of life with no gender difference. The major-
ity of TSH-omas are large adenomas. Clinically they run with mild
to moderately severe symptoms of hyperthyroidism. Patients are
characterized by elevated levels of free thyroid hormones together
with the lack of suppression of TSH secretion. Almost all TSH-
omas express a variable number of somatostatin receptors what
prompted the use of somatostatin analogues in their treatment.
Somatostatin analogues induce a significant tumour mass shrink-
age in about 40% of patients and normalization of circulating thy-
roid hormones in more than 90% of them. TSH-omas require
differentiation with the resistance to thyroid hormone action syn-
drome (RTH).
Aims
To present two patients with central hyperthyroidism caused by TSH-
secreting pituitary adenomas.
Materials and methods
The analysis of clinical picture and hormonal and imaging studies.
Results
Case 1. 69-year-old patient with pituitary macroadenoma [40 x 25
x 25 mm], incidentally detected in MRI performed during diagno-
sis of vertigo. All pituitary hormones were normal, but IGF-1 con-
centration was low [<0.25 ng/mL; n > 63.9]. Insufficiency of
pituitary-gonadal axis was present [testosterone = 56.41 ng/dL;
n > 242]. There were neither clinical signs of hyperthyroidism nor
visual defects observed. The concentrations of thyroid hormones
were: FT4 = 37.8 pmol/L [n: 12.0-22.0]; FT3 = 15.9 pmol/L [n: 3.0-
7.0]; TSH = 1.61 mIU/L [n: 0.2-4.9]. Thyroid ultrasound revealed the
presence of 73 ml nodular goitre. An increase of TSH of about
0.21 mIU/L during the TRH-TSH test excluded the diagnosis of
RTH syndrome. The patient was treated with the use of thiamazol
(periodically) together with long-acting somatostatin analogue (8
injections). The size of the tumour has not decreased. After reach-
ing the normalization of thyroid function, the transsphenoidal sur-
gery was conducted.
Case 2. 49-year-old patient, diagnosed due to weight loss, weakness
and arrhythmias. He also didn’t complain of visual field defects. All
pituitary hormones were normal. Failure of the pituitary-adrenal axis
(ACTH = 23.17 pg/mL and cortisol circadian rhythm = 3.2——2.1 μg/
dL) and pituitary-gonadal axis (testosterone = 95.8 ng/dL) were ob-
served. Low IGF-1 level = 47.2 ng/mL (n > 94 ng/mL) was also certi-
fied. Thyroid hormones and TSH level were increased: FT4 = 5.91 ng/
dL [n: 0.89-1.76]; FT3 > 20.0 pg/mL [n: 2.3-4.2]; TSH = 6.57 mIU/L [n:
0.55-4.78]. Thyroid ultrasound revealed the presence of nodular
goitre. MRI picture showed 37 x 33 x 34 mm tumour mass localized
in sella turcica and suprasellar region, penetrating to the pituitary
stalk, optic chiasm, sphenoid sinus and right cavernous sinus. TRH-
TSH test showed a decrease in TSH level. The patient has been ini-
tially treated with thiamazol followed by long-acting somatostatin
analogue (4 doses). Partial regression of the tumour has been
achieved. Currently neurosurgery is planned.
Conclusions
In parallel to the symptoms of central hyperthyroidism patients with
TSH-omas also present other disturbances generated by the presence
of macroadenomas. These signs can affect the course of the disease
and require an acknowledgement in the diagnostic and treatment
procedures. Patients with thyrotropinomas are characterized by dif-
ferent course of the disease and heterogenic response to therapy
with somatostatin analogue.
Consent for publication
The authors acquired written informed consent from the patients.A29
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Autoimmune thyroid disease (AITD) comprises autoimmune thyroid-
itis (Hashimoto’s thyroiditis, HT) and Graves’ disease (GD) including
Graves’ ophthalmopathy (Graves’ orbitopathy, GO). In addition to
these, we may also distinguish subclinical autoimmune thyroid dis-
ease characterized by the increased anti-thyroid antibodies without
any clinical manifestations.
The frequency of AITD is estimated to be 5%, whereas the frequency
of subclinical AITD is even higher, with a female: male ratio ranging
from 5:1 to 10:1. This gender difference seems to be caused by parity
(in relation to fetal microchimerisms), and the phenomenon of
skewed XCI (skewed X- chromosome inactivation).
Although clinical manifestations of AITD are different; both are char-
acterized by thyroid lymphocytic infiltration and the production of
thyroid antibodies.
The etiopathogenesis of AITD is multifactorial and it is the result of
an interaction between genetic susceptibility and environmental trig-
gers leading to the breakdown of immunological tolerance and the
development of AITD.
Among the environmental factors the most important are: smoking,
iodine excess, selenium deficiency, bacterial (i.e. Yersinia enterocoli-
tica) and viral (i.e. HCV) infections, various medications such as amio-
darone, interferon alpha, alumtuzumab and others.
Susceptibility genes involved in the etiopathogenesis of AITD can
be divided into thyroid-specific genes and immunoregulatory
genes. Identified thyroid-specific genes are TSHR and Tg. The im-
mune regulatory genes predisposing to AITD include: HLA-DR class
II, CTLA-4, P TPN22, CD25, CD40 and many others. It seems to be
that HLA-DR beta –Arg 74 plays a critical mechanistic role in the de-
velopment of AITD.
It is interesting that, with the exception of HLA-DR, most loci, which
are associated with AITD, give low odd ratios (OR: 1.5-2.0). Thus, epi-
genetic modulations include DNA methylation, histone modifications
and RNA interference by miR; may interact with genetic and environ-
mental factors in the development of AITD.
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Background
Medullary thyroid carcinoma (MTC) is often diagnosed in an ad-
vanced stage, with the presence of metastases. Among possible
treatments the use of protein kinase inhibitors inspires hope, al-
though actually their wider application is limited. Many surveys
showed the expression of somatostatin receptors (SSTR) on the cells
of the MCT, which justifies the fact of using somatostatin analogues,
labelled with emitters of beta-radiation in therapy.
Aims
The aim of the survey was to assess the side effects of treatment
with 90-yttrium (90-Y) and 177-lutetium (177-Lu) radiolabelled som-
atostatin analogue in patients with advanced MTC.
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The analyzed group includes 8 patients aged between 47 to 77 years
with diagnosed advanced MCT, who were treated with four doses of
90Y/177Lu-DOTA-TATE, each of the activity 1.48/1.48 GBq, given at
12-week intervals. The toxicity of the treatment was assessed using
CTCAE v. 4.03, considering biochemical parameters, such as haemo-
globin level, neutrophils count, creatinine and liver transaminase
levels. The parameters were assessed before treatment, after the
treatment and after finishing the cycle.
Results
Among five patients who received the whole cycle of treatment,
in three there was a decrease of 2 g/dL in haemoglobin levels ob-
served, two of them had an additional increase of 0.2 mg/dL in
creatinine levels, but none matched the criteria of an adverse
event following CTCAE v. 4.03. Among the three remaining pa-
tients who still have not completed the cycle of treatment there
were no adverse events observed between administration of the
doses thus far.
Conclusions
In all patients the treatment was well tolerated, there were no ad-
verse events matching the criteria of CTCAE. The lack of serious side
effects may be caused by the interval between doses and the use of
a protective infusion of amino acids before and after each treatment.
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Background
Chronic autoimmune thyroiditis (cAIT) and Graves' disease (GD) are
the most common autoimmune disorders in children. TNF-α is associ-
ated with induction of inflammation and autoimmunity process. Os-
teoprotegerin is a soluble glycoprotein and a member of the tumour
necrosis factor receptor (TNFR) family and plays an important role in
bone homeostasis, autoimmune disorders and vascular diseases.
Aims
To determine concentrations of TNF-α and OPG in autoimmune thy-
roid disease (AITD) in children.
Materials and methods
We studied serum TNF-α and OPG (ELISA) in 22 newly diagnosed
children with cAIT, 22 GD children and 20 healthy subjects with nor-
mal FT4, FT3, TSH and negative antithyroid Abs.
Results
In our study OPG concentrations were significantly higher in children
with GD (median; IQR; range) (4.68 pmol/L; 2.86; 1.17-8.30) compared
to control group (3.00 pmol/L; 1.98; 1.46-5.51)(p < 0.01). No significant
difference was observed between TNF-α serum concentrations in
cAIT (15.08 pg/mL; 21.94; 0.00-143.4) and GD group (13.63 pg/mL;
15.28; 0.00-28.5) vs control group (0.96 pg/mL; 12.81; 0.00-17.7) (p =
0.067). In children with hyperthyroidism we identified significant
positive correlations between cytokines: TNF-α and OPG (r = 0.69; p <
0.01), while in the group with hypothyroidism, a significant correl-
ation of TNF-α and ATPO (r = 0.54; p < 0.01). ROC curve analysis indi-
cates that TNF-α differentiates children with hypothyroidism and
healthy children AUC = 0.691; p = 0.034 with sensitivity of 54.5%, but
a good specificity of 85%. On the contrary, OPG may be a marker of
hyperthyroidism and exhibits a good discriminatory efficacy betweengroup of hyperthyroid children and healthy children: AUC = 0.716;
p = 0.017 at cut-off point of 4.54 pmol/L, with low sensitivity 54.5%
but high specificity 95%.
Conclusions
Based on performed study we can consider TNF-α as a marker of
hypothyroidism and OPG as a marker of hyperthyroidism in children
with AITD.
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Nontoxic multinodular goitre (MNG) is frequently observed in the
general population, but still little is known about the underlying
genetic susceptibility to this disease. The terms adenomatous
goitre, nontoxic nodular goitre and colloid nodular goitre are used
interchangeably as descriptive terms when a MNG is found. Several
hereditary tumour syndromes such as Carney complex, PTEN
hamartoma tumour syndrome, Werner syndrome and APC-associ-
ated polyposis can be associated with non-neoplastic MNG how-
ever differentiated thyroid cancer can also occur. There are several
factors that may be involved in the evolution of multinodular
goitre: (1) primary - due to genetic abnormalities in several genes
(the thyroglobulin-gene, the thyroid peroxidase-gene, the sodium-
iodide-symporter-gene, the Pendred syndrome-gene, the TSH
receptor-gene, the iodotyrosine deiodinase and the thyroid oxidase
2 gene3 leading subsequently to functional and structural abnor-
malities in growing goitres and (2) secondary such as elevated TSH
as a potent stimulator of thyrocyte proliferation (induced by iodine
deficiency, natural goitrogens, inborn errors of thyroid hormone
synthesis), autoimmune thyroiditis (primary – intrathyroidal mech-
anism – disregulated apoptosis, and secondary - TSH-dependent
nodules), smoking, stress, certain drugs, other thyroid-stimulating
factors (IGF-1 and others) and endogenous factor (gender). Differ-
ent somatic mutations are found in TSHR gene and the majority of
mutations that are present in toxic adenomas are also found in
toxic nodules in multinodular goitre. Germline mutations in the
TSHR gene cause non-autoimmune autosomal dominant hyperthy-
roidism and in some patients with MNG.
Germline mutations in DICER1, a gene that codes for an RNase III
endoribonuclease, disregulating miRNA expression pattern, have
been identified in families affected by pleuropulmonary blastoma
(PPB), some of whom include cases of MNG and gonadal tumours
such as Sertoli-Leydig Cell Tumors (SLCTs). Moreover the other tu-
mours such as cystic nephroma, embryonal rhabdomyosarcomas,
Wilms tumors and other very rare entities, all comprise DICER1 syn-
drome inherited in autosomal dominant pattern but with unknown
penetrance. Cystic and hyperplastic thyroid abnormalities are a com-
mon finding in the DICER1 syndrome with MNG, characterized by
multinodular thyroid hyperplasia, being particularly prevalent in
DICER1 carriers, likely higher than that for neoplasms. Based on the
literature it is hypothesized that this second somatic “hit” in DICER1
is required in addition to a loss of-function germ-line DICER1 muta-
tion in order to initiate thyroid carcinoma development. A genetic
counselling and testing should be offered to the family of the af-
fected child.
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Thyroid Research 2016, 9(Suppl 1):6 Page 21 of 24Acromegaly is a chronic clinical condition resulting from prolonged
exposure of the tissues to excess production of growth hormone by
a pituitary tumour and, as a consequence, increased concentration of
insulin-like growth factor (IGF-1). In the course of the disease charac-
teristic changes of the patients’ appearance, as well as metabolic and
systemic complications occur. One of the most important conse-
quences of the disease is an increased risk of neoplastic transform-
ation. Neoplasms, following cardiovascular and pulmonary diseases,
constitute a third leading cause of death in patients suffering from
acromegaly. Hence, proper diagnostics and introduction of adequate
treatment of concomitant diseases are crucial in the management of
patients with acromegaly, in order to improve their comfort of life
and to avoid preterm death. The incidence of thyroid cancer and
nodular goitre is high in acromegalic patients. Available data suggest
that acromegaly is associated with a statistically significant increase
in thyroid cancer risk compared to the general population. The risk is
particularly high in subjects with an active or poorly controlled dis-
ease. Therefore, in order to detect neoplastic disease early and im-
prove the prognosis, acromegalic patients require careful thyroid
monitoring, including thyroid ultrasound examination and fine-
needle aspiration biopsy, both at the diagnosis stage and during
follow-ups. However, sonoelastography proves to be of limited value
in the prediction of thyroid nodules malignancy diagnosed in acro-
megalic patients.
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The common hallmark of malignant tumours is their ability to
metastasize. One of the key markers of lymphangiogenesis is home-
otic transcription factor-1 (Prox1). Several studies suggested that
Prox1 protein plays an important role in carcinogenesis. The role of
Prox1 has been described in several cancer.
The aim of our study was to determine Prox1 expression and exam-
ine its function in the biology of follicular thyroid cancer.
Our research was performed on cell lines derived from follicular
thyroid cancer: FTC-133 (metastasis to the lymph nodes) and CGTH
-W-2 (metastasis to sternum). Immortalized normal thyroid cell line
(NTHY-ori-3) was used as a control. Prox1 mRNA and protein
expression were determined using Q-RT-PCR, Western Blot and
immunocytochemistry.
Role of Prox1 in the regulation of hallmarks of the malignant cell
phenotype (migration, invasiveness, anchorage-independent growth
and changes in cell morphology) was analyzed in cells upon Prox1 si-
lencing or overexpression. To elucidate regulatory pathways involved
in the observed phenotype we have applied Akt kinase inhibitor.
Prox1 transcript and protein levels were overexpressed in FTC133
and CGTH lines when compared with NTHY. Moreover, the protein
was localized in the nucleus or both the nucleus and cytoplasm, re-
spectively. Prox1 gene silencing decreased, whereas overexpression
increased migration and the invasive potential. Changes in the Prox1
expression strongly influenced cytoskeleton and cells morphology.
Moreover, we observed correlation between the Prox1 and the Akt
kinase expression .
Our data suggest that the nuclear transcription factor Prox1 may play
important role in the mechanism of follicular thyroid cancer cells
metastasis.Presented work was supported by grant 2012/07/B/NZ5/02444 and
213/11/N/NZ5/03394 from The National Science Center, Poland
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Background
Obesity in children leads to a number of metabolic and hormonal
disorders. Among the hormonal disturbances the thyroid dysfunction
is dominant. It is not clear whether it is the cause or the conse-
quence of excess body weight.
Aims
To evaluate thyroid function in children with simple obesity compared
to their peers with normal weight.
Material and methods
The study included 110 obese children (5-18 years) and 38
healthy peers. All patients underwent anthropometric measure-
ments and laboratory tests (TSH, FT4, fasting glucose, triglycerides
- TG, total cholesterol - TC, LDL-cholesterol, HDL-cholesterol). They
calculated BMI-SDS, the waist to hip ratio (WHR) and the waist to
height ratio (WHtR).
Results
Mean TSH concentrations in the obese children were statistically signifi-
cantly higher than in children with normal weight (2.1 ± 1.0 μIU/mL vs.
1.5 ± 0.6 μIU/mL, p = 0.000). Mean concentrations of FT4 were compar-
able in both subgroups (1.0 ± 0.2 ng/dL vs. 1.0 ± 0.1 ng/dL, p = 0.589). In
the whole study group TSH correlated with BMI-SDS (r = 0.333, p =
0.000), WHR (r = 0.326, p = 0.000), WHtR (r = 0.282, p = 0.001) and TC (r =
0.364, p = 0.000), LDL cholesterol (r = 0.333, p = 0.000), TG (r = 0.280, p =
0.001). FT4 concentration correlated only with body weight (r = - 0.213,
p = 0.013) and the hip circumference (r = - 0.194, p = 0.024).
Conclusions
TSH concentrations observed in obese children were significantly
higher compared with their peers with normal weight and correlated
with the degree of abdominal obesity.
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Studies evaluating the quality of life (QoL) in patients with
Graves' orbitopathy (GO) have shown that their QoL is profoundly
impaired. Notable, QoL assessed by patient does not correlate
with objective parameters such as duration of the disease, GO ac-
tivity and severity. The prevalence of anxiety and depression is
higher than in healthy population. GO has an impact on social
and economic functioning, leading to temporary or permanent
disability to work. GO should be considered a chronic disease be-
cause patients experience lower QoL even 11 years after therapy.
The European Group on Graves' orbitopathy (EUGOGO) recom-
mended using QoL questionnaire to assess patients' QoL as a
part of clinical evaluation. In addition, EUGOGO recommended
that the therapeutic decision in mild GO should be based on
QoL measurement. The Polish version of GO-QoL questionnaire is
now available and we recommend its use for evaluation of Polish
GO patients.
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Background
Fine needle aspiration biopsy (FNAB) is a diagnostic method of
choice in differential diagnosis of thyroid lesions, however it has
some limitations. They may result from ambiguous cytological pic-
ture of the lesions connected with concomitant inflammatory
process. The most common thyroiditis is Hashimoto’s disease. A
common finding in thyroid follicular cells in this disorder is oxy-
philic metaplasia. Nuclear features in such cells are mainly: large
hyperchromatic nucleus, prominent nucleolus, sometimes vacuoles
and intranuclear grooves, i.e. features of papillary thyroid cancer.
Case report
42-year-old female patient with asthma and rheumatoid arthritis,
treated for a few years with levothyroxine because of chronic auto-
immune thyroiditis, was sent to the Endocrinology Outpatient Clinic.
She had no complaints and no abnormalities were found in the
physical examination. Laboratory tests revealed TSH 2,10 uIU/ml (n
0,27-4,32), TPOAb 480 IU/ml (n 0-34). Thyroid ultrasound showed a
solid, normoechoic lesion 12x8mm on the border of the right lobe
and isthmus. FNAB was performed and the result was: suspicion of
papillary thyroid cancer, characterized as Bethesda category V. The
patient underwent thyroidectomy and eventually a benign lesion
and chronic lymphocytic thyroiditis were reported in the histopatho-
logical examination.
Discussion
Cytological diagnosis of thyroid nodules, especially in patients with
chronic autoimmune thyroiditis is sometimes a challenge for a path-
ologist and may be associated with formulating ambiguous or even
false positive results. In the face of these limitations, it seems to be
justified to include molecular procedures to the assessment of thy-
roid nodules in patients with chronic autoimmune thyroiditis.
Conclusion
Presence of the nodular chronic autoimmune thyroiditis hinders
preoperative cytological diagnosis of thyroid lesions.
Consent for publication
The authors acquired written informed consent from the patient.
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In the clinical practice patients with hypothyroidism who are on
levothyroxine (LT4) therapy often complain of symptoms characteris-
tic for thyroid hormone deficiency despite having TSH level within
the norm range.
The aim of the study was to assess the role of free triiodothyronine
(FT3) concentration in the evaluation of the therapy of patients with
primary hypothyroidism.It was a prospective study. Patients included to the study group were
on LT4 replacement therapy and had normal TSH level, and had
complaints suggesting thyroid hormone deficiency.
The exclusion criteria were: thyroid cancer or another active neoplas-
tic disease, pituitary gland insufficiency, liver and kidney diseases,
use of medications: liothyronine, metformin, proton pump inhibitors,
H2 antagonists, oral contraceptives, hormonal replacement therapy,
calcium and iron preparations. In the study group the initial concen-
trations of TSH, free thyroxine (FT4), FT3 before and after increase of
LT4 dose were measured. The quality of life initially and after in-
crease of the dose was assessed using the questionnaire ThyPROpl.
Thirty three women of 37 patients completed the study (mean
age 48.7 y). The initial mean concentration of TSH was 1.81 μU/
mL ± 0.78 μU/mL, and FT4 16.73 pmol/L ± 1.85 pmol/L; median
(IQR) FT3 3.94 pmol/L (3.74-4.29). After the increase of the dose of
LT4 the mean ± SD: TSH - 0.64 μU/mL ± 0.49 μU/mL; FT4 – 19.43 pmol/
L ± 1.55 pmol/L; FT3 – 4.75 pmol/L ± 0,54 pmol/L.
After the increase of LT4 dose the symptoms of hypothyroidism de-
creased, improvement of cognitive functions, emotional irritability,
tiredness, anxiety, mood, daily activity, social activity, sexual func-
tions, and goitre symptoms was observed. The lower FT3 concen-
tration was associated with the anxiety, depression, emotional
irritability, and goitre symptoms.
The increase of FT3 concentration in patients treated with LT4 is as-
sociated with the improvement of their quality of life.
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Thyroid embryogenesis is a complex and still unexplained process,
with suspected of genetic background. Causative mutations were
found in only a few percent of patients, mostly with severe thyroid
developmental abnormalities leading to congenital hypothyroidism
(agenesis, ectopy, hypoplasia).
In our study, we conducted sequencing and MLPA analysis of se-
lected genes, known to be involved in thyroid embryogenesis. More-
over, an attempt to identify novel genetic factors through genomic
studies (microarray, whole exome sequencing) was made. The stud-
ied group consisted of 34 patients with sporadic form of thyroid
hemiagenesis (TH) and one family, where HT was transmitted from a
mother to daughter. Several novel genes potentially involved in thy-
roid development were identified. They are engaged in the following
biological processes: a) protein degradation via proteasome b) mem-
brane transport c) cytoskeleton d) transcription regulation. Novel
genetic alterations were found in the genes encoding different sub-
units of proteasome and also genes functionally related to proteoso-
mal protein degradation. Haploinsufficiency of these genes may
negatively impact developmental processes. Novel research indicate
potential role of mutations in proteosomal subunits in numerous dis-
eases (congenital, cardiovascular, neurological, autoimmune, neo-
plasms). The postulated mechanism of the disease indicates a toxic
effect of undegraded protein accumulation. In conclusion, the identi-
fied alterations in patients with TH support the hypothesis of genetic
background of the anomaly. Mutations in proteasomal genes might
be causative in at least some portion of TH cases, and conceivably
other thyroid developmental abnormalities. Our project is the first
genomic study performed in such big cohort of patients with TH. Ap-
plication of novel screening techniques allows for identification of
novel candidate genes for TH and shed a new light on etiopathogen-
esis of thyroid dysgenesis, so far in majority reported to be associ-
ated with mutations in thyroid transcription factors.
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Polycystic ovary syndrome (PCOS) and thyroid diseases are the most
common endocrine dysfunction in women of reproductive age. De-
pending on criteria applied the frequency of PCOS is estimated at
8.7-17.8%. Hypothyroidism is diagnosed in about 3%, hyperthyroid-
ism in 0.6% of menstruating women, however the thyroid antibodies
positivity is encountered in up to 18% of that group. Many studies
have confirmed that the thyroid autoimmunity is more frequent in
PCOS women (OR of 4.8 for autoimmune thyroiditis in PCOS women
according to Du et al. [1]), as well as higher prevalence of PCOS in
women with autoimmune thyroiditis, regardless the TSH level. The
nature of the association between thyroid dysfunction and PCOS has
not been elucidated. The role of the genetic factors has been postu-
lated. For example the polymorphism of fibrillin 3 (FBN3) gene, regu-
lating the activity of the TGFβ cytokines has been suggested to be
involved in the pathogenesis of both entities, however the true link-
age has not been proven yet. The variants of GnRH receptor gene
has been linked both with TSH level and insulin sensitivity, which
pays an important role in PCOS pathogenesis. Polymorphisms of the
genes encoding enzymes of steroid hormones metabolism pathway
may also be involved. Also sex hormones themselves may at least
partially explain the increased joint prevalence of thyroid auto-
immunity and PCOS, which is characterized by relative hyperestro-
genaemia. Estrogens, progesterone and prolactin are postulated to
increase susceptibility to autoimmune disorders. Estrogen receptors
are present in immune cells, such as Th1 and Th2 lymphocytes, and
monocytes/macrophages. Increasing levels of estrogens are involved
in shift to Th2-mediated immunity, increased regulatory T cell forma-
tion and increased activity of B cells. Arduc et al. [2] in a case-control
study have shown positive correlation between TPO antibodies titre
and both estrogen levels and estrogen/progesterone ratio.
It seems that autoimmune thyroiditis and subclinical hypothyroidism
are not related to the PCOS fenotype. The other question is whether
coexistence of autoimmune thyroid disease and/or hypothyroidism
influences the PCOS-related metabolic risk. The currently available
data are conflicting. Subclinical hypothyroidism has been shown to
be related to reduced insulin sensitivity and increased LDL choles-
terol and triglycerides levels in PCOS patients, however it is not clear
if it is due to hypothyroidism itself or rather do to increased BMI and
waist-to-hip ratio. However, for example Mueller et al. [3] have dem-
onstrated that TSH level above 2 mIU/L can be an independent risk
factor of insulin resistance.
The influence of PCOS treatment on hypothalamus-pituitary- thyroid
axis should also be considered. Metformin is reported to lower TSH in
hypothyroid patients, both under and without L-thyroxine (LT4) treat-
ment. No such effect is seen in euthyroid patients not treated with LT4.
Similar effects have been observed in PCOS patients. Thyroid diseases
(particularly autoimmunity) may negatively influence PCOS treatment
outcomes, particularly infertility. Ott et al. [4] for example have noticed
higher titre of TPO antibodies in PCOS patients resistant to clomiphene
citrate and metformin.
Concluding. PCOS and thyroid diseases, particularly thyroid autoimmun-
ity, are frequent co-morbidities. The nature and consequences of this as-
sociation still need to be explained. A PCOS patient, however, requires a
close assessment of thyroid function to avoid possible negative effect of
thyroid dysfunction on her general and reproductive health.
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Thyroid hormones are essential regulators of the cell development
and function. Their serum concentration is under precise control of
hypothalamus-pituitary-axis via feedback regulatory system. Differ-
ences in the sensitivity to thyroid hormones might be responsible for
some disturbances in psychosomatic development, low quality of life
and not effective supplementation of thyroid hormones preparations.
Responsiveness to thyroid hormones is related to properly function-
ing system of hormones transmembrane transfer, deiodination and
binding with specific nuclear receptor. Among the major groups of
carriers contributing to thyroid hormones transport across the cell
membrane one should mention: MCT (MCT8, MCT10), OATP (OATP1C,
OATP1A2, OATP1A4) and LAT (LAT1, LAT2) and NCTP. Although MCT
8 has a specific affinity to thyroid hormones, the remaining proteins
are transporting also aromatic amino acids (MCT10), organic anions
(OATP), large, neutral amino acids (LAT). Very important elements of
transport system are the escort proteins (e.g. 4F2hc) that drive syn-
thesized proteins to the cell membrane.
The defect of gene coding thyroid hormone transporter, known as
Allan-Herndon-Dudley syndrome, was reported. Clinical manifestation
comprises intellectual disability, spastic paraplegia, involuntary move-
ments, joint contractures and high serum T3, low serum T4 and nor-
mal or slightly elevated TSH. An inactivating recessive mutation of
SLC16A2 gene located on X-chromosome and coding for MCT8 trans-
porter cause the syndrome. Polymorphisms in a gene coding
OATP1C1 protein were also published and were referring to quality
of life in patients treated with L-thyroxine.
Thyroid hormones that are effectively transported via cell membrane
bind directly to specific nuclear receptors (T3) or undergo deiodina-
tion (T4 > T3) by deiodinase 1 or 2. Deiodinases activity might be
modulated by genetic or environmental factors.
Until now, no crucial defects of deiodinases’ genes were reported,
but it was found that autosomal recessive mutation in SECISBP2 gene
coding for protein contributing to incorporation of selenocysteine
into selenoproteins in important way decrease deiodinase activity.
Patients affected by this mutation present increased serum T4 con-
centration with increased TSH (although its level could be in the nor-
mal range) and decreased serum T3. Clinical manifestation comprises
delayed growth, bone age and in some cases also impaired intellec-
tual development, myopathy, hearing loss, infertility and immune de-
ficiency. It has been demonstrated that polymorphisms of deiodinase
1 (DIO1) or deiodinase 2 (DIO2) genes might be related to variability
of thyroid hormone concentration in serum, decreased quality of life
in patients treated with L-thyroxine or to responsiveness to com-
bined T3/T4 therapy.
Thyroid hormones bind to specific receptor in nucleus and mito-
chondria and mostly form heterodimer with retinoid X receptor.
Thyroid hormones receptors are considered as transcription factors.
The major isoforms showing high affinity to T3 are THRb1, THRb2
and THRa1. Binding of T3 to its receptor releases corepressors and
leads to attachment of cofactors what triggers transcription. Apart
from direct impact on transcription regulation, the thyroid hor-
mones act via nongenomic (non-classical) pathway that is related
to MAP kinase and Pi3K and regulate expression of FGF, GLUT1 or
MCT4 proteins.
Thyroid Research 2016, 9(Suppl 1):6 Page 24 of 24Resistance to thyroid hormones is a rare disorder with prevalence
reaching approximately 1:40000 live births. This condition is caused
by dominating mutations of TRHb gene, mostly leading to elevated
T3, T4 and TSH being consequence of disturbances in negative feed-
back. Goitre and tachycardia are frequent symptoms. Abnormal coch-
lea development, impaired neural development and colour vision
may also occur. Mutations within TRHa gene appears with lower fre-
quency and lead to mild serum thyroid hormone disturbances. These
defects are manifested by delayed bone development, chronic con-
stipation, bradycardia and impaired neural development. In selected
patients presenting similar signs and symptoms, which were previ-
ously described, no genetic defect was identified.
Increased sensitivity to thyroid hormones was described in mouse
model lacking THRa gene. Recently, late onset resistance to thyroid
hormones caused by various point mutations within TRHb gene was
reported. It was manifested principally by goitre and palpitations,
weakness or hyperactivity were not so common.
Except genetic factors, the sensitivity to thyroid hormones might
be influenced by environmental factors and general patient’s health
status. The responsiveness might be reduced in case of stress, in-
jury, inflammation, low calorie diet, toxins or severe liver and kid-
neys diseases.
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Thyroid Research 2016, 9(Suppl 1):A42Coexistence of thyroid diseases and diabetes is frequent and this has
important clinical and therapeutic implications. Epidemiological data
on the prevalence of thyroid diseases in the population with diabetes
are divergent and indicate the percentage of between five and over
thirty percent, similarly in type 1 and type 2 diabetes. As in the general
population, the problem affects women more often than men.
Forty three percent of the participants Poznan Prospective Study
(PoProStu) with type 1 diabetes have positive tyrosine peroxidase
antibodies (TPO Ab), including significantly more often in women
(53%) than men (21%). Epidemiological data indicate the advisability
of screening for thyroid dysfunction in patients with diabetes.
The frequent co-occurrence of thyroid disease and diabetes is patho-
physiological justified.
Autoimmune thyroid disease (AITD) and type 1 diabetes have a com-
mon genetic and environmental background. The association of
major histocompatibility complex (MHC) and human leucocyte anti-
gens (HLA) class II (HLA-DR) with these diseases has been known for
over 30 years and remains the strongest, although finding a plurality
of new consecutive genes associated with autoimmune process.
The negative impact of environmental factors, on the one hand inter-
fere through epigenetic mechanisms, on the other metabolic
phenomenon can be focused to insulin resistance, inflammation and
oxidative stress. Both hyperthyroidism and hypothyroidism disrupt
the regulation of energy homeostasis.
In people with diabetes, hyperthyroidism leads to faster absorption
of carbohydrates from the gastrointestinal tract and promotes post-
prandial hyperglycaemia, increases hepatic glucose production, lip-
olysis and ketogenesis. Clinically, this translates into fluctuation of
glycaemia, the occurrence of the dawn phenomenon, increased risk
of ketoacidosis and increased demand for insulin.
On the other hand thyroid hormone deficiency is characterized by
impaired glucose absorption from the gastrointestinal tract, reduced
hepatic glucose production and decreased peripheral tissue glucose
disposal. The clinical consequences in patients with diabetes are pri-
marily associated with a decrease in insulin requirements, and in-
creased risk of hypoglycaemia, including severe episodes.
Association of insulin resistance with thyroid diseases has not only
functional but also structural background. It has been shown that in-
sulin resistance has goitrogenic effect. In patients with abdominal
obesity and metabolic syndrome larger volume of thyroid and more
likely to have thyroid nodules was noticed. In addition, the associ-
ation of insulin resistance with thyroid cancer is still discussed.
The significance of coexisting comorbidity of AITD and type 1 dia-
betes in assessment of the risk of development of late diabetic com-
plications is uncertain. Surprisingly, it was demonstrated that adults
with type 1 diabetes and positive thyroid antibodies develop less mi-
croangiopathy in comparison to group without AITD.
The higher knowledge in the theme of thyroid disease and diabetes,
the more significant need for greater understanding and clinical
sensitivity allowing for improvement of diagnostic and therapeutic
effectiveness in the coexistence of these diseases.•  We accept pre-submission inquiries 
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